A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)
Phase: PHASE2
Conditions: Severe to Critical COVID 19 With Associated ARDS
Sponsor: Foresee Pharmaceuticals Co., Ltd.

 
 
CLINICAL STUDY PROTOCOL 
 
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, 
Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in 
Patients With Severe to Critical COVID-19 With Associated Acute 
Respiratory Distress Syndrome (ARDS) 
Investigational Product: FP-025 
Protocol Number: FP02C-20-001 
Investigational New Drug Number: IND 151602 
 
 
Sponsor: 
Foresee Pharmaceuticals, Co. Ltd. 
201 Marshall Street, Suite 103 
Redwood City, CA 94063 
United States 
Telephone: 650-518-9886 
 
 
Version Number: 3.0 
Original Protocol: 16 December 2020 
Amendment 1: 27 January 2021 
Amendment 2: 12 May 2021 
 
 
Confidentiality Statement 
The information in this document is confidential and is not to be disclosed without the written 
consent of Foresee Pharmaceuticals, Co. Ltd. except to the extent that disclosure would be 
required by law and for the purpose of evaluating and/or conducting a clinical study for Foresee 
Pharmaceuticals, Co. Ltd. You are allowed to disclose the contents of this document only to your 
Institutional Review Board and study personnel directly involved with conducting this protocol. 
Persons to whom the information is disclosed must be informed that the information is 
confidential and proprietary to Foresee Pharmaceuticals, Co. Ltd. and that it may not be further 
disclosed to third parties. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 2 of 74 
Version 3.0, 12 May 2021 
SIGNATURE PAGE 
STUDY TITLE: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multicenter 
Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical 
COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS) 
 
We, the undersigned, have read this protocol and agree that it contains all necessary information 
required to conduct the study. 
Signature 
 
 
 
 
 
 
 
Date 
 
David Lau, PhD 
Senior Vice President, NCE Development 
Foresee Pharmaceuticals, Co. Ltd. 
 
Yisheng Lee, MD 
Chief Medical Officer 
Foresee Pharmaceuticals, Co. Ltd. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 3 of 74 
Version 3.0, 12 May 2021 
INVESTIGATOR AGREEMENT 
By signing below I agree that: 
I have read this protocol. I approve this document and I agree that it contains all necessary details 
for carrying out the study as described. I will conduct this study in accordance with the design and 
specific provision of this protocol and will make a reasonable effort to complete the study within 
the time designated. I will provide copies of this protocol and access to all information furnished 
by Foresee Pharmaceuticals, Co. Ltd. to study personnel under my supervision. I will discuss this 
material with them to ensure they are fully informed about the study product and study procedures. 
I will let them know that this information is confidential and proprietary to Foresee 
Pharmaceuticals, Co. Ltd. and that it may not be further disclosed to third parties. I understand that 
the study may be terminated or enrollment suspended at any time by Foresee 
Pharmaceuticals, Co. Ltd., with or without cause, or by me if it becomes necessary to protect the 
best interests of the study patients. 
I agree to conduct this study in full accordance with Food and Drug Administration Regulations, 
Institutional Review Board/Ethic Committee Regulations and International Council for 
Harmonisation Guidelines for Good Clinical Practices. 
 
 
 
 
 
 
______________________________________________  
____________________ 
Investigator’s Signature 
 
 
 
 
 
Date 
 
 
 
______________________________________________ 
Investigator’s Printed Name 
 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 4 of 74 
Version 3.0, 12 May 2021 
SYNOPSIS 
TITLE: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to 
Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID-19 With 
Associated Acute Respiratory Distress Syndrome (ARDS) 
PROTOCOL NUMBER: FP02C-20-001 
INVESTIGATIONAL PRODUCT: FP-025 (a selective small molecule inhibitor of matrix 
metalloproteinase [MMP]-12) 
PHASE: 2/3 
INDICATION: Severe to critical coronavirus (CoV) disease 2019 (COVID-19) with associated 
acute respiratory distress syndrome (ARDS) 
OBJECTIVES: 
The primary objectives of this study are the following: 
• To evaluate the efficacy of FP-025, compared to placebo, in adult patients with severe to 
critical COVID-19 with associated ARDS, when used with standard of care treatment for 
COVID-19; and 
• To evaluate the safety and tolerability of FP-025 in adult patients with severe to critical 
COVID-19 with associated ARDS. 
The secondary objectives of this study are the following: 
• To evaluate the efficacy of FP-025, compared to placebo, in improving acute COVID-19 
outcomes as measured by the change over time in the National Institute of Allergy and 
Infectious Diseases (NIAID) 8-point ordinal scale for COVID-19 and hospitalization 
outcomes, when used with standard of care treatment for COVID-19; 
• To evaluate the efficacy of FP-025, compared to placebo, in reducing or preventing pulmonary 
fibrosis as determined by quantitative high-resolution, non-contrast computed tomography 
(CT) scan, when used with standard of care treatment for COVID-19; 
• To evaluate the effect of FP-025, compared to placebo, on pulmonary function testing, when 
used with standard of care treatment for COVID-19; 
• To evaluate the effect of FP-025, compared to placebo, on renal function in adult patients with 
severe to critical COVID-19 with associated ARDS; and 
• To assess the pharmacokinetics (PK) of FP-025 in adult patients with severe to critical 
COVID-19 with associated ARDS. 
The exploratory objective of this study is to evaluate the effect of FP-025, compared to placebo, 
on inflammatory and fibrotic biomarkers in blood when used with standard of care treatment for 
COVID-19. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 5 of 74 
Version 3.0, 12 May 2021 
POPULATION: 
The population for this study will include male or female patients ≥18 years with a diagnosis of 
severe to critical COVID-19 with associated ARDS. 
Inclusion criteria: 
Patients who meet all of the following criteria will be eligible to participate in the study: 
1. Is willing to provide informed consent (or has a legally authorized representative [LAR] 
willing to provide informed consent) and is willing and able (or has an LAR willing and able) 
to comply with the protocol-required therapy, monitoring, and follow-up; 
2. Is a male or female aged ≥18 years; 
3. Has a COVID-19 diagnosis confirmed by a documented, positive severe acute respiratory 
syndrome (SARS)-CoV-2 reverse transcriptase polymerase chain reaction test (or equivalent 
test) immediately prior to or during the current hospitalization; 
4. Is hospitalized with severe to critical COVID-19 within a 72-hour period prior to the Screening 
Visit and meeting the following characteristics: 
o Diagnosed with ARDS based on the Berlin criteria as follows: 
 Respiratory symptoms developed within 1 week of a known clinical insult or new or 
worsening respiratory symptoms developed during the past week; 
 Chest radiograph or computed tomography scan shows bilateral opacities not fully 
explained by pleural effusions, lobar or lung collapse, or pulmonary nodules; and 
 Respiratory failure is not fully explained by cardiac failure or fluid overload; and 
o Requiring at least 1 of the following: 
 Endotracheal intubation and mechanical ventilation;  
 Oxygen delivered by high flow nasal cannula (heated, humidified oxygen delivered 
via reinforced nasal cannula at flow rates >20 L/minute with a fraction of delivered 
oxygen ≥0.5);  
 Non-invasive positive pressure ventilation; or  
 Clinical diagnosis of respiratory failure (ie, the clinical need for 1 of the preceding 
therapies, but preceding therapies are unable to be administered in the setting of 
resource limitations);  
5. If female, is post-menopausal for at least 1 year, surgically sterile (documented by medical 
record), or a woman of childbearing potential (WCBP) who agrees to use a highly effective 
method of birth control (ie, method with a failure rate <1% per year) from enrollment until 
30 days following the last dose of study drug. Highly effective methods of birth control are 
defined as follows: complete sexual abstinence, intrauterine device, intrauterine 
hormone-releasing system, progestogen-only hormonal contraception (implant, injectable, or 
oral), and combined (estrogen and progestogen) contraception (oral, intravaginal, or 
transdermal); 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 6 of 74 
Version 3.0, 12 May 2021 
6. If a WCBP, must have a negative serum human chorionic gonadotropin (hCG) pregnancy test 
at the Screening Visit (or have a negative historical serum hCG within the 24 hours before the 
Screening Visit) and must agree to monthly urine pregnancy tests during the study; and 
7. If male, must be surgically sterile for at least 1 year prior to the Screening Visit (documented 
by medical record), or must agree to use a double barrier approach (eg, condoms with 
spermicide) during sexual intercourse between the Screening Visit and at least 90 days after 
administration of the last dose of study drug. Male patients must ensure that non-pregnant 
female partners of childbearing potential comply with the contraception requirements in 
Inclusion Criterion 5. 
Exclusion criteria: 
Patients who meet any of the following criteria will be excluded from participation in the study: 
1. Is not expected to survive more than 24 hours; 
2. Is on extracorporeal membrane oxygenation (ECMO) at the Screening Visit; 
3. Has an underlying clinical condition where, in the opinion of the Investigator, it would be 
extremely unlikely that the patient would come off ventilation (eg, motor neuron disease, 
Duchenne muscular dystrophy, or rapidly progressive pulmonary fibrosis); 
4. Has a known history of idiopathic pulmonary fibrosis or interstitial lung disease as defined by 
the American Thoracic Society 2018 guidelines; 
5. Has known active tuberculosis (TB), a history of incompletely treated TB, and/or suspected 
or known extrapulmonary TB; 
6. Has Child-Pugh Class B or C active liver disease or an alanine aminotransferase or aspartate 
aminotransferase level >4 × the upper limit of normal at the Screening Visit; 
7. Has moderate to severe renal insufficiency, defined as an estimated glomerular filtration 
rate (eGFR) ≤30 mL/min/1.73 m2, at the Screening Visit or requires hemodialysis; 
8. Has a malignant tumor (excluding a malignant tumor cured with no recurrence in the past 
5 years, completely resected basal cell and squamous cell carcinoma of skin, and/or 
completely resected carcinoma in situ of any type); 
9. Has an uncontrolled systemic or local autoimmune or inflammatory disease besides 
COVID-19; 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 7 of 74 
Version 3.0, 12 May 2021 
10. Has evidence of an active concurrent non-COVID-19 pneumonia that requires additional 
antimicrobial treatment at the time of the Screening Visit and is caused by a known or 
suspected bacterial pathogen, respiratory syncytial virus (RSV), influenza virus, 
SARS-CoV-1, Middle East respiratory syndrome-CoV, aspergillus, mucormycosis-causing 
fungi, or other pulmonary pathogen(s);  
Note: If a viral respiratory panel has not been collected within the 24 hours prior to the 
Screening Visit, a viral respiratory panel will be administered at the Screening Visit to 
determine eligibility. At a minimum, the panel will evaluate for RSV, influenza A, and 
influenza B. 
11. Has received any other investigational therapeutic products within 4 weeks or 5 half-lives, 
whichever is longer, prior to randomization; 
12. Has a known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C 
infection; 
13. Has a known serious allergic reaction or hypersensitivity to any components of FP-025; 
14. Is pregnant or breastfeeding; 
15. Has a history of drug or alcohol abuse within the past 2 years; 
16. Is currently on another systemic immunomodulatory therapy that is not considered standard 
of care treatment for COVID-19 (eg, calcineurin inhibitor, hydroxychloroquine, anti-cytokine 
therapy, or Janus kinase inhibitor); 
Note: Corticosteroids, including dexamethasone, in doses used for standard of care treatment 
for COVID-19 are allowed.  
Note: Corticosteroids that are being used for other indications are also allowed as long as the 
daily prednisone (or other corticosteroid equivalent) dose is ≤10 mg. Inhaled corticosteroids 
and nasal corticosteroids are also acceptable.  
Note: As therapies for COVID-19 are rapidly evolving, other medications that may be 
considered standard of care can be considered with prior approval from the Sponsor or Medical 
Monitor. 
17. Is currently on a strong cytochrome P450 inducer or inhibitor; or  
18. Has any other condition that, in the opinion of the Investigator, could interfere with (or for 
which the treatment might interfere with) the conduct of the study or interpretation of the study 
results or that would place the patient at undue risk by participating in the study. 
STUDY DESIGN AND DURATION: 
This is a Phase 2/3, randomized, double-blind, placebo-controlled, multicenter study to evaluate 
the efficacy and safety of FP-025 in adult patients with severe to critical COVID-19 with 
associated ARDS. The patients in each phase (Phase 2 and Phase 3) will be analyzed separately. 
Each phase will consist of a Screening Visit, Treatment Period, and Follow-Up Period for a total 
study duration of approximately 60 days. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 8 of 74 
Version 3.0, 12 May 2021 
Phase 2: 
After eligibility is confirmed, approximately 99 patients will be randomized in a 1:1:1 ratio to 
receive FP-025 100 mg twice daily (BID), FP-025 300 mg BID, or placebo BID for 28 days. 
During Phase 2, randomized patients will be stratified by the use of invasive mechanical 
ventilation at the time of randomization (yes or no). At least one-third of patients should be on 
invasive mechanical ventilation to ensure that treatment benefits can be assessed for patients at 
different severity levels. 
Patients with Grade 3 to Grade 4 heart failure, Stage 3 or greater chronic obstructive pulmonary 
disease, persistent asthma, and mild liver disease (ie, Child-Pugh Class A) will not be excluded 
from the study. The independent Data Monitoring Committee (iDMC) will independently monitor 
safety of the entire population and in different subgroups and may make recommendations as it 
deems appropriate. During Phase 2, no limitation in enrollment of subgroups is expected, unless 
clear safety signals arise in those subgroups during iDMC reviews. 
The reason for hospital admission, the standard of care followed for each patient and center, and 
whether any care decisions were based on resource limitations will be clearly documented for all 
patients beginning on Day 1 (Visit 2). All patients will be allowed to receive standard of care 
and/or emergency use authorization (EUA) medications and treatment for COVID-19; however, 
the study drug should be discontinued for other non-standard of care concomitant medications 
used with the intent of directly treating COVID-19 unless there is prior Medical Monitor or 
Sponsor approval for the patient to remain on the study drug. If the use of concomitant medications 
necessitates study drug discontinuation, the patient should be encouraged to remain in the study 
and to follow-up for key study visits (Day 28 and Day 60) but will not be required to attend every 
study visit. If the patient withdraws, he/she should complete the Early Termination Visit.  
Standard of care procedures for mechanical ventilation (eg, low tidal volume protective 
mechanical ventilation) and standard of care procedures for weaning from mechanical ventilation 
will be followed. 
Study drug administration will begin on Day 1 (Visit 2) following randomization. All patients will 
receive standard of care and/or EUA treatment for COVID-19 in addition to the study drug. 
Patients will continue study drug treatment BID through Day 27 and take 1 dose on Day 28. If a 
patient is discharged from the hospital prior to Day 28, he/she will continue treatment as an 
outpatient at home with his/her assigned treatment (FP-025 100 mg BID, FP-025 300 mg BID, or 
placebo BID) until Day 28. Dosing instructions will be provided prior to discharge. Although 
treatment will be identical for inpatients and outpatients, patients discharged from the hospital will 
follow a different Schedule of Procedures, characterized by telemedicine (or telephone, if sites 
and/or patients do not have video capability) visits. The End of Treatment (EOT) Visit on Day 28 
will be identical for all patients (with the exception of the arterial oxygen partial pressure 
[PaO2]/fractional inspired oxygen [FiO2] ratio, performed only in patients on invasive or 
non-invasive ventilation) and will include a high-resolution, non-contrast CT scan, in addition to 
other assessments. 
After treatment is completed, all patients will undergo 2 follow-up assessments during the 
Follow-Up Period. The first follow-up will be a telephone visit on Day 45 to assess concomitant 
medications, adverse events (AEs), and the NIAID 8-point ordinal scale for COVID-19 and 
hospitalization outcomes score. The second follow-up will be an in-person visit on Day 60 and 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 9 of 74 
Version 3.0, 12 May 2021 
will include a high-resolution, non-contrast CT scan and pulmonary function tests, in addition to 
other assessments. 
An iDMC will convene to oversee safety and efficacy assessments during and after the Phase 2 
study. The first iDMC meeting will occur after approximately 10 to 15 patients have been enrolled. 
The second iDMC meeting will occur after approximately 50% to 60% of patients have been 
enrolled. No formal statistical testing will be conducted. In addition, when all patients in the 
Phase 2 study have completed the EOT Visit on Day 28, a primary analysis will be conducted by 
an independent statistician and reviewed by the iDMC. 
Phase 3: 
Based on the results of the primary analysis of Phase 2, 1 optimal dose will be selected to carry 
into Phase 3. Once the optimal dose has been selected, the study may proceed to Phase 3. Patients 
will be randomized in a 1:1 ratio to receive FP-025 or placebo for 28 days. Similar procedures 
will be followed as for Phase 2; however, study design (eg, eligibility criteria, sample size number, 
protocol-defined procedures, and timing of procedures) or dosing may be changed based on iDMC 
recommendations after data from the primary analysis in Phase 2 becomes available. If the iDMC 
recommends modification of the protocol, and the Sponsor is in agreement, the protocol will be 
amended and submitted to regulatory authorities and Institutional Review Boards for approval. 
An interim analysis will be conducted after approximately 70% (213 out of 304) of the randomized 
patients have completed the EOT Visit on Day 28 or have discontinued early, but would have 
reached Day 28 had they remained in the study, to assess for safety, early futility, and potential 
sample size recalculation. 
DOSAGE FORMS AND ROUTE OF ADMINISTRATION: 
FP-025 is supplied as an oral capsule (amorphous solid dispersion-in-capsule) at a dose strength 
of 50 mg per capsule, and will be stored at room temperature (ie, 20°C to 25°C [68°F to 77°F]) 
under secure conditions. It will be administered orally as capsules or via a polyvinyl chloride 
nasogastric tube (by opening up the capsules and delivering as a suspension in orange juice). 
Capsules can also be opened and added to orange juice to drink. During Phase 2, patients will be 
randomized in a 1:1:1 ratio to receive FP-025 100 mg BID, FP-025 300 mg BID, or placebo BID 
for 28 days, starting on Day 1 (Visit 2). Patients in each dose group will receive a total of 
6 capsules during each dosing session as follows: 
• FP-025 100 mg BID: Two 50 mg capsules and 4 placebo capsules; 
• FP-025 300 mg BID: Six 50 mg capsules; and 
• Placebo: 6 placebo capsules. 
Based on the results of the primary analysis of Phase 2, 1 optimal dose will be selected to carry 
into Phase 3, and patients will be randomized in a 1:1 ratio to receive FP-025 or placebo for 
28 days. No dose adjustments will be performed for renal impairment.  

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 10 of 74 
Version 3.0, 12 May 2021 
EFFICACY ENDPOINTS:  
For all endpoints defined by events, the time points are defined as the number of days after 
randomization. 
The primary efficacy endpoint is the proportion of patients alive and not requiring non-invasive 
or invasive ventilation (ie, not receiving high-flow nasal cannula, non-invasive positive pressure 
ventilation, invasive mechanical ventilation, or ECMO) at Day 28, with each dose (Phase 2) or 
the optimal dose (Phase 3) of FP-025 compared to placebo. 
The key secondary efficacy endpoints include the following, with each dose (Phase 2) or the 
optimal dose (Phase 3) of FP-025 compared to placebo: 
• Proportion of patients on invasive mechanical ventilation at Day 28; 
• Proportion of patients alive at Day 28; 
• Proportion of patients alive and not requiring non-invasive or invasive ventilation (ie, not 
receiving high-flow nasal cannula, non-invasive positive pressure ventilation, invasive 
mechanical ventilation, or ECMO) at Day 60; 
• Proportion of patients on invasive mechanical ventilation at Day 60; and 
• Proportion of patients alive at Day 60. 
The other secondary efficacy endpoints include the following, with each dose (Phase 2) or the 
optimal dose (Phase 3) of FP-025 compared to placebo: 
• Quantitative assessment of lung fibrosis at Day 28 and at Day 60 using high-resolution, 
non-contrast CT scan; 
• Proportion of patients who were randomized on invasive mechanical ventilation who are free 
of invasive mechanical ventilation at Day 28 and at Day 60; 
• Number of ventilator-free days (ie, days free of invasive mechanical ventilation) at Day 28 
and at Day 60; 
• Number of intensive care unit (ICU)-free days at Day 28 and at Day 60; 
• Number of days in the hospital at Day 28 and at Day 60; 
• Change from baseline in peripheral capillary oxygen saturation at Day 28 and at Day 60; 
• Change from baseline in PaO2/FiO2 ratio at Day 28 and at Day 60 (patients on invasive or 
non-invasive ventilation only); 
• Proportion of patients alive and not hospitalized at Day 28 and at Day 60; 
• Proportion of patients with disease progression (defined as a ≥2-point decrease in the NIAID 
8-point ordinal scale score or death) at Day 28 and at Day 60; 
• Proportion of patients who improve by ≥2 points on the NIAID 8-point ordinal scale scores at 
Day 28 and proportion of patients who improve by ≥2 points at Day 60; 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 11 of 74 
Version 3.0, 12 May 2021 
• Pulmonary function at Day 28 (if possible based on the patient’s clinical condition per the 
judgment of the Investigator) and at Day 60 (all patients) based on the following scores: 
o Forced vital capacity (FVC); 
o Forced expiratory volume in 1 second (FEV1); 
o FEV1/FVC ratios; and 
o Diffusing capacity of the lungs for carbon monoxide; and 
• Change from baseline in eGFR, blood urea nitrogen, and serum creatinine at Day 28 and 
Day 60. 
Exploratory endpoints will include the change from baseline (pre-dose on Day 1) in biomarkers 
related to pulmonary inflammation, fibrosis and/or lung injury at Day 7, Day 14, Day 28, and 
Day 60, including but not limited to the following, with each dose (Phase 2) or the optimal dose 
(Phase 3) of FP-025 compared to placebo:  
• MMP-12, MMP-7, and MMP-9; 
• Transforming growth factor-β; 
• Connective tissue growth factor;  
• C-reactive protein (CRP); 
• Cytokines (interferon-γ, tumor necrosis factor-α, interleukin [IL]-6, IL-1β, and C-C motif 
chemokine ligand 2 [monocyte chemoattractant protein-1]);  
• Ferritin; 
• Released N-terminal pro-peptide of type III collagen; 
• Internal epitope in the 7S domain of type IV collagen; 
• C-terminal of released C5 domain of type VI collagen α3 chain (endotrophin); 
• Neo-epitope of MMP-2, 9, and 13-mediated degradation of type I collagen; 
• Neo-epitope of MMP-2, 9, and 12-mediated degradation of type IV collagen; 
• Neo-epitope of MMP-2-mediated degradation of type VI collagen; 
• Neo-epitope of MMP-1 and 8-mediated degradation of CRP; and 
• Neo-epitope of plasmin-mediated degradation of cross-linked fibrin. 
Additional biomarkers not listed here may be evaluated at a future date. 
SAFETY ENDPOINTS: 
The safety endpoints include the following:  
• AEs and serious AEs (SAEs); 
• Clinical laboratory assessments (including clinical chemistry, hematology, and urinalysis); 
• Vital signs; 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 12 of 74 
Version 3.0, 12 May 2021 
• Physical examinations; and 
• 12-lead electrocardiograms (ECGs). 
AEs will be monitored and recorded from the time of the first dose of study drug (Day 1 [Visit 2]) 
until the end of the study (Day 60). All events occurring prior to the first dose of study drug will 
be recorded as medical history. 
Any SAE that is ongoing at the end of the study (Day 60) will be followed by the Investigator 
until the SAE has subsided or until the condition(s) becomes chronic in nature, until the patient 
begins alternative treatment for COVID-19, until the condition(s) stabilizes (in the case of 
persistent impairment), or until the patient dies.  
As events of progression of the patient’s underlying COVID-19 diagnosis will be captured as 
efficacy endpoints, these events should not be reported as AEs or SAEs unless considered related 
to the study drug or a study procedure or if the outcome is fatal during the study and within the 
safety reporting period. Additionally, expected events for ARDS that are perceived by the 
Investigator to occur with reasonable frequency in the day-to-day care of patients with ARDS 
treated in an ICU setting with mechanical ventilation will not be reported as AEs. Examples of 
events that are expected in the course of ARDS include transient hypoxemia, agitation, delirium, 
etc. Such events, which are often the focus of prevention efforts as part of standard ICU care, will 
not be considered reportable AEs unless the event is considered by the Investigator to be 
associated with the study drug or study procedures, is unexpectedly severe or frequent, or is a 
change of severity for an individual patient with ARDS. 
PHARMACOKINETIC ENDPOINT: 
The PK endpoint is the plasma exposure of FP-025 at each dose level. Sampling times will be as 
follows: 
• Day 1 (Visit 2): pre-dose, 1 hour (±10 minutes), 3 hours (±10 minutes), and 8 hours 
(±10 minutes) post the first morning dose of study drug; 
Note: If the patient is randomized in the afternoon on Day 1 (Visit 2), this will be performed 
after the morning dose of study drug on Day 2. 
• Day 4, Day 7, Day 14, and Day 21: within 1 hour (±10 minutes) prior to the morning dose; 
and 
• Day 28: within 1 hour (±10 minutes) prior to the morning dose and 1 hour (±10 minutes) 
post-morning dose. 
STATISTICAL ANALYSES: 
The following analysis populations are defined for this study: 
Intent-to-Treat (ITT) Population: The ITT Population is defined as all randomized patients. The 
ITT Population will be the primary population for analysis of efficacy data. Efficacy analyses will 
be based on the assigned treatment group. 
Safety Population: The Safety Population is defined as all randomized patients who receive at 
least 1 dose of study drug. All safety data will be analyzed using the Safety Population. Safety 
analyses will be based on the treatment actually received. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 13 of 74 
Version 3.0, 12 May 2021 
Per-Protocol (PP) Population: The PP Population is defined as all patients in the ITT Population 
who complete the study with no major protocol deviations that may impact the primary efficacy 
assessment. The primary analysis will be repeated on the PP Population. Major protocol deviations 
will include violations of key entry criteria or deviations that could significantly impact the 
assessment or interpretation of efficacy data. 
PK Population: The PK Population is defined as all patients with at least 1 PK measurement drawn 
during the study. 
Patients who discontinue the study drug will remain in the study to have safety and efficacy 
assessments performed. Patients should be encouraged to follow-up for key study visits (Day 28 
and Day 60) but will not be required to attend every study visit. The data observed on-study will 
be used for analysis regardless of any intercurrent events. Patients who die or discontinue 
treatment prior to the assessment time point (Day 28 or Day 60) because of lack of efficacy, and 
cannot have clinical status determined at the time point, will be considered treatment failures. 
Details regarding data handling and imputation method will be provided in the Statistical Analysis 
Plan (SAP).  
The primary efficacy endpoint is the proportion of patients alive and not requiring non-invasive 
or invasive ventilation (ie, not receiving high-flow nasal cannula, non-invasive positive pressure 
ventilation, invasive mechanical ventilation, or ECMO) at Day 28. The treatment group difference 
of the response proportions, along with the corresponding 95% confidence interval and p-value, 
will be provided using the logistic regression model by Guo et al. (2012) and Ge et al. (2011), 
adjusted for stratification factor (use of invasive mechanical ventilation at the time of 
randomization [yes or no]). Additional prognostic baseline covariates (eg, age, region, body mass 
index) may be added as covariates/factors into the model to increase precision in the estimation 
of difference in proportions. Details will be provided in the SAP.  
The primary analysis will be repeated on the PP Population.  
The key secondary endpoints of the proportion of patients alive and not requiring non-invasive or 
invasive ventilation (ie, not receiving high-flow nasal cannula, non-invasive positive pressure 
ventilation, invasive mechanical ventilation, or ECMO) at Day 60, the proportion of patients on 
invasive mechanical ventilation at Day 28 and at Day 60, and the proportion of patients alive at 
Day 28 and Day 60, will be analyzed using the same method as for the primary analysis. 
Tipping point method will be used as a sensitivity analysis for evaluating the robustness of the 
results for the primary endpoint and key secondary endpoints. 
Other secondary endpoints will be analyzed as described in the SAP. For all endpoints defined by 
events, the time points are defined as the number of days after randomization. 
The Phase 2 study is not powered. No alpha controlling strategy will be implemented.  
To control the overall Type I error in the final analysis for Phase 3, a fixed sequential testing 
procedure will be implemented. In a hierarchical step-down manner, the primary efficacy endpoint 
will be tested at the 1-sided 0.025 level first, followed by testing the secondary efficacy endpoints 
at the 1-sided 0.025 level in the following hierarchical manner: (1) proportion of patients on 
invasive mechanical ventilation at Day 28, (2) proportion of patients alive at Day 28, 
(3) proportion of patients alive and not requiring non-invasive or invasive ventilation (ie, not 
receiving high-flow nasal cannula, non-invasive positive pressure ventilation, invasive 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 14 of 74 
Version 3.0, 12 May 2021 
mechanical ventilation, or ECMO) at Day 60, (4) proportion of patients on invasive mechanical 
ventilation at Day 60, and (5) proportion of patients alive at Day 60.  
Inferential conclusions about these efficacy endpoints will require statistical significance of the 
previous endpoints and the primary efficacy endpoint. 
This is not applicable to Phase 2 since Phase 2 is not powered.  
PK data will be summarized. 
Safety data will be summarized by actual treatment received, and in total for selected 
analyses/summaries, based on the Safety Population, and include the following: 
• AEs and SAEs; 
• Clinical laboratory assessments (including clinical chemistry, hematology, and urinalysis); 
• Vital signs; 
• Physical examinations; and 
• 12-lead ECGs. 
ANALYSIS TIMING: 
Primary analysis (Phase 2): 
A primary analysis will be conducted once all patients in Phase 2 complete the EOT Visit on 
Day 28 or have discontinued early but would have reached Day 28 had they remained in the study. 
The results will be conducted by an independent statistician and reviewed by the iDMC following 
the procedures defined in the iDMC Charter. The iDMC will convene to recommend dose 
selection and whether to adjust study design for Phase 3 based on this analysis. The study team 
will remain blinded. Designated personnel from the Sponsor will have access to the analysis 
results. The Phase 3 sample size and interim analysis boundaries will be recalculated based on the 
Phase 2 primary analysis results. 
Final analysis (Phase 2 and Phase 3): 
For each phase (Phase 2 and Phase 3), after all the patients have completed (discontinued) the 
study and the database is locked, the data will be unblinded and the final analysis will be 
performed. 
Interim analysis: 
No interim analysis is planned for Phase 2. 
For Phase 3, an interim analysis will be performed once approximately 70% of the randomized 
patients complete the EOT Visit on Day 28 or have discontinued early but would have reached 
Day 28 had they remained in the study. The iDMC will convene to evaluate for safety, early 
futility, and potential sample size recalculation.  
INDEPENDENT DATA MONITORING COMMITTEE: 
An iDMC with multidisciplinary representation and pertinent expertise will be established to 
evaluate accumulating study data and to oversee the ongoing safety of the study for the patients 
enrolled. The iDMC will be external to the Sponsor. The iDMC will meet at 4 scheduled times, as 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 15 of 74 
Version 3.0, 12 May 2021 
described below, and more frequently if needed, to provide safety oversight for patients. Only the 
iDMC members and an independent statistician will have access to unblinded comparative results. 
The study team will remain blinded, except as noted above for the Phase 2 primary analysis. 
The iDMC will convene during the Phase 2 study at 2 pre-planned time points, once after 
approximately 10 to 15 patients have been enrolled and a second time after approximately 50% to 
60% of patients have been enrolled. For each pre-planned meeting, the decision to have an 
associated pause in enrollment will be made by the chairperson of the iDMC (with input from the 
Medical Monitor). The decision will be based on the type of safety data to be provided for review 
and taking into account whether continuing enrollment could place study patients at risk. Based 
on safety and efficacy evaluations using unblinded data, the iDMC may make recommendation(s) 
to the Sponsor to continue the study with or without modifications or, for safety reasons, terminate 
the study. The Sponsor will make the final decision to terminate the study. No formal statistical 
testing will be conducted. 
In addition, a primary analysis will be conducted once all patients in the Phase 2 study complete 
the EOT Visit on Day 28. The analysis will be conducted by an independent statistician and 
reviewed by the iDMC. The Sponsor (key personnel only) will also be able to review the data at 
this time. The iDMC will convene to recommend dose selection and whether to adjust study design 
(eg, eligibility criteria, sample size number, protocol-defined procedures, and timing of 
procedures) for Phase 3 based on this analysis. If the iDMC recommends modification of the 
protocol, and the Sponsor is in agreement, the protocol will be amended. Enrollment of any 
patients for Phase 3 will not begin until after completion of the assessment of the primary analysis. 
During the Phase 3 study, an interim analysis will be performed once approximately 70% of the 
randomized patients (approximately 213 patients) complete the EOT Visit on Day 28 or have 
discontinued early but would have reached Day 28 had they remained in the study. Enrollment of 
new patients will be paused during the interim analysis. The iDMC will convene, evaluating for 
safety, early futility, and potential sample size recalculation. The interim analysis of the primary 
endpoint will be for early futility only. The study will not be stopped for overwhelming efficacy. 
Based on ongoing safety monitoring of the study, additional ad hoc iDMC reviews may be 
conducted. For these ad hoc meetings, the decision to have an associated pause in enrollment will 
be made by the chairperson of the iDMC (with input from the Medical Monitor). Further details 
regarding the role, responsibilities, and procedures of the iDMC will be provided in the iDMC 
Charter.  
In addition, manual reviews of safety data will be performed throughout the study by appropriate 
study personnel and the Medical Monitor. Study personnel and the Medical Monitor will be 
blinded to the patient treatment assignments throughout the study; however, in the event of an 
emergency or AE for which it is necessary to know the study drug to determine an appropriate 
course of therapy for the patient, unblinding may occur. 
SAMPLE SIZE DETERMINATION: 
For the Phase 2 study, approximately 99 patients will be randomized in a 1:1:1 ratio to 1 of 
3 treatment groups: FP-025 100 mg BID, FP-025 300 mg BID, or placebo BID. No formal 
statistical assessment for sample size determination has been performed. The sample size is 
considered adequate to provide the necessary data to evaluate the objectives of the study. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 16 of 74 
Version 3.0, 12 May 2021 
For Phase 3, a total of 304 patients (152 patients per treatment group) will provide approximately 
80% power to detect a 15% improvement in response rate, based on a control response rate of 
60% and assuming a response rate of 75% with the study drug treatment group, using a 1-sided 
0.025 level test. The sample size estimate assumes that an interim analysis will be conducted after 
approximately 70% of patients (approximately 213 patients) have completed the EOT Visit on 
Day 28 or have discontinued early, but would have reached Day 28 had they remained in the study, 
to assess early futility and potential sample size recalculation. The sample size was calculated 
using EAST 6.4. The Phase 3 sample size will be formally recalculated based on results from the 
Phase 2 part of the study. A maximum of 608 patients may be included. If the iDMC, in 
consultation with the Sponsor determines that a sample size of more than 608 patients is needed, 
a protocol amendment will be required. 
SPONSOR: 
Foresee Pharmaceuticals, Co. Ltd. 
201 Marshall Street, Suite 103 
Redwood City, CA 94063 
United States 
Telephone: 650-518-9886 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 17 of 74 
Version 3.0, 12 May 2021 
TABLE OF CONTENTS 
Signature Page ................................................................................................................................ 2 
Investigator Agreement ................................................................................................................... 3 
Synopsis .......................................................................................................................................... 4 
Table of Contents .......................................................................................................................... 17 
List of Tables ................................................................................................................................ 21 
List of Abbreviations and Definition of Terms............................................................................. 22 
1 Introduction and Background Information ............................................................................. 24 
1.1 
Coronavirus Disease 2019 ............................................................................................. 24 
1.2 
FP-025 ........................................................................................................................... 25 
1.3 
Rationale ........................................................................................................................ 26 
1.4 
Risk/Benefit ................................................................................................................... 26 
2 Study Objectives ..................................................................................................................... 27 
2.1 
Primary Objectives ........................................................................................................ 27 
2.2 
Secondary Objectives .................................................................................................... 27 
2.3 
Exploratory Objective ................................................................................................... 27 
3 Study Description.................................................................................................................... 28 
3.1 
Summary of Study Design ............................................................................................ 28 
3.1.1 
Phase 2 .......................................................................................................... 28 
3.1.2 
Phase 3 .......................................................................................................... 29 
3.2 
Study Indication ............................................................................................................ 29 
4 Selection and Withdrawal of Patients ..................................................................................... 30 
4.1 
Inclusion Criteria ........................................................................................................... 30 
4.2 
Exclusion Criteria .......................................................................................................... 31 
4.3 
Stopping Criteria ........................................................................................................... 32 
4.3.1 
Criteria for Potential Interruption or Discontinuation of Study Drug in 
Individual Patients ........................................................................................ 32 
4.3.2 
Criteria for Potential Study Termination ...................................................... 33 
4.4 
Withdrawal Criteria ....................................................................................................... 33 
5 Study Treatments .................................................................................................................... 35 
5.1 
Treatment Groups .......................................................................................................... 35 
5.2 
Rationale for Dosing ..................................................................................................... 35 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 18 of 74 
Version 3.0, 12 May 2021 
5.3 
Randomization and Blinding ......................................................................................... 35 
5.4 
Breaking the Blind ........................................................................................................ 35 
5.5 
Drug Supplies ................................................................................................................ 36 
5.5.1 
Formulation and Packaging .......................................................................... 36 
5.5.2 
Study Drug Preparation and Dispensing ...................................................... 36 
5.5.3 
Study Drug Administration .......................................................................... 36 
5.5.4 
Treatment Compliance ................................................................................. 36 
5.5.5 
Storage and Accountability .......................................................................... 36 
5.6 
Prior and Concomitant Medications and/or Procedures ................................................ 37 
5.6.1 
Excluded Medications and/or Procedures .................................................... 37 
5.6.2 
Documentation of Prior and Concomitant Medication Use ......................... 37 
6 Study Procedures .................................................................................................................... 39 
7 Efficacy and Pharmacokinetic Assessments ........................................................................... 40 
7.1 
Efficacy and Pharmacokinetic Endpoints ..................................................................... 40 
7.1.1 
Primary Efficacy Endpoint ........................................................................... 40 
7.1.2 
Key Secondary Efficacy Endpoints .............................................................. 40 
7.1.3 
Other Secondary Efficacy Endpoints ........................................................... 40 
7.1.4 
Exploratory Endpoints .................................................................................. 41 
7.1.5 
Pharmacokinetic Endpoint ............................................................................ 42 
7.2 
Efficacy Assessments .................................................................................................... 42 
7.2.1 
Arterial Oxygen Partial Pressure/Fractional Inspired Oxygen Ratio ........... 42 
7.2.2 
Pulmonary Function Tests ............................................................................ 42 
7.2.3 
Computed Tomography Scan ....................................................................... 42 
7.2.4 
Inflammatory and Fibrotic Biomarker Analysis ........................................... 42 
7.2.5 
National Institute of Allergy and Infectious Diseases 8-Point Ordinal 
Scale ............................................................................................................. 43 
7.3 
Other Assessments ........................................................................................................ 43 
7.3.1 
Severe Acute Respiratory Syndrome Coronavirus-2 Testing ...................... 43 
8 Safety Assessments ................................................................................................................. 44 
8.1 
Adverse Events .............................................................................................................. 44 
8.1.1 
Adverse (Drug) Reaction .............................................................................. 44 
8.1.2 
Unexpected Adverse Drug Reaction ............................................................ 45 
8.1.3 
Assessment of Adverse Events by the Investigator ...................................... 45 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 19 of 74 
Version 3.0, 12 May 2021 
8.1.4 
Expected Acute Respiratory Distress Syndrome Events .............................. 46 
8.2 
Serious Adverse Events ................................................................................................. 46 
8.3 
Serious Adverse Event Reporting − Procedures for Investigators ................................ 47 
8.4 
Pregnancy Reporting ..................................................................................................... 48 
8.5 
Expedited Reporting ...................................................................................................... 48 
8.6 
Special Situation Reports .............................................................................................. 49 
8.7 
Safety Endpoints ........................................................................................................... 50 
8.8 
Clinical Laboratory Assessments .................................................................................. 50 
8.9 
Pregnancy Test .............................................................................................................. 50 
8.10 Vital Signs ..................................................................................................................... 50 
8.11 Electrocardiograms ........................................................................................................ 50 
8.12 Physical Examinations .................................................................................................. 50 
9 Statistics .................................................................................................................................. 52 
9.1 
Analysis Populations ..................................................................................................... 52 
9.2 
Statistical Methods ........................................................................................................ 52 
9.2.1 
Analysis of Efficacy ..................................................................................... 52 
9.2.1.1 Primary efficacy analysis .................................................................... 52 
9.2.1.2 Secondary efficacy analysis ................................................................ 52 
9.2.1.3 Multiplicity in Phase 3 ........................................................................ 53 
9.2.1.4 Pharmacokinetic analysis .................................................................... 53 
9.2.2 
Analysis of Safety ......................................................................................... 53 
9.2.3 
Analysis Timing ........................................................................................... 53 
9.2.4 
Independent Data Monitoring Committee .................................................... 55 
9.2.5 
Sample Size Determination .......................................................................... 56 
10 Data Management and Record Keeping ................................................................................. 57 
10.1 Data Management ......................................................................................................... 57 
10.1.1 
Data Handling ............................................................................................... 57 
10.1.2 
Computer Systems ........................................................................................ 57 
10.1.3 
Data Entry ..................................................................................................... 57 
10.1.4 
Medical Information Coding ........................................................................ 57 
10.1.5 
Data Validation ............................................................................................. 57 
10.2 Record Keeping ............................................................................................................. 57 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 20 of 74 
Version 3.0, 12 May 2021 
10.3 End of Study .................................................................................................................. 58 
11 Investigator Requirements and Quality Control ..................................................................... 59 
11.1 Ethical Conduct of the Study ........................................................................................ 59 
11.2 Institutional Review Board ............................................................................................ 59 
11.3 Informed Consent .......................................................................................................... 59 
11.4 Study Monitoring Requirements ................................................................................... 59 
11.5 Disclosure of Data ......................................................................................................... 60 
11.6 Retention of Records ..................................................................................................... 60 
11.7 Publication Policy ......................................................................................................... 60 
11.8 Financial Disclosure ...................................................................................................... 61 
12 Study Administrative Information .......................................................................................... 62 
12.1 Protocol Amendments ................................................................................................... 62 
13 References ............................................................................................................................... 63 
Appendix A: Schedule of Procedures ........................................................................................... 65 
Appendix B: Clinical Laboratory Analytes .................................................................................. 70 
Appendix C: National Institute of Allergy and Infectious Diseases 8-Point Ordinal Scale for 
COVID-19 and Hospitalization Outcomes ............................................................................. 72 
Appendix D: Suggested Criteria for Mechanical Ventilation Weaning and Extubation .............. 73 
Appendix E: Strong Clinical Inhibitors and Inducers for Cytochrome P450-Mediated 
Metabolisms ............................................................................................................................ 74 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 21 of 74 
Version 3.0, 12 May 2021 
LIST OF TABLES 
Table 1. 
Futility Boundaries in the Interim and Final Analyses of Overall Success Rate Based 
on a 1-Sided Test at the 0.025 Level........................................................................... 54 
Table 2. 
Schedule of Procedures: Inpatient Admission Through Day 28 ................................. 65 
Table 3. 
Modified Schedule of Procedures for Discharged Patients ........................................ 68 
Table 4. 
NIAID 8-Point Ordinal Scale for COVID-19 and Hospitalization Outcomes ........... 72 
Table 5. 
Suggested Criteria for Mechanical Ventilation Weaning and Extubation .................. 73 
Table 6. 
Strong Inhibitors and Inducers of Cytochrome P450 ................................................. 74 
 
 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 22 of 74 
Version 3.0, 12 May 2021 
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS  
Abbreviation 
Definition 
AE 
Adverse event 
ARDS 
Acute respiratory distress syndrome 
BAL 
Bronchoalveolar lavage 
BID 
Twice daily 
CD 
Cluster of differentiation 
CFR 
Code of Federal Regulations 
COPD 
Chronic obstructive pulmonary disease 
CoV 
Coronavirus(es) 
COVID-19 
Coronavirus disease 2019 
CRA 
Clinical research associate 
CRP 
C-reactive protein 
CT 
Computed tomography  
CTCAE 
Common Terminology Criteria for Adverse Events 
ECG 
Electrocardiogram 
ECMO 
Extracorporeal membrane oxygenation 
eCRF 
Electronic case report form 
EDC 
Electronic data capture 
eGFR 
Estimated glomerular filtration rate 
EIU 
Exposure In Utero 
EOT 
End of Treatment 
EUA 
Emergency use authorization 
FDA 
Food and Drug Administration 
FEV1 
Forced expiratory volume in 1 second 
FiO2 
Fractional inspired oxygen 
FVC 
Forced vital capacity 
GCP 
Good Clinical Practice 
GLP 
Good Laboratory Practice 
hCG 
Human chorionic gonadotropin 
HIV 
Human immunodeficiency virus 
ICF 
Informed consent form 
ICH 
International Council for Harmonisation 
ICU 
Intensive care unit 
iDMC 
Independent Data Monitoring Committee  
IFN 
Interferon 
IL 
Interleukin 
IRB 
Institutional Review Board 
ITT 
Intent-to-Treat 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 23 of 74 
Version 3.0, 12 May 2021 
Abbreviation 
Definition 
LAR 
Legally authorized representative 
LPS 
Lipopolysaccharide 
MERS 
Middle East respiratory syndrome  
MMP 
Matrix metalloproteinase 
NIAID 
National Institute of Allergy and Infectious Diseases 
PaO2 
Arterial oxygen partial pressure 
PFT 
Pulmonary function test 
PK 
Pharmacokinetic(s) 
PP 
Per-Protocol 
RSV 
Respiratory syncytial virus 
SAE 
Serious adverse event 
SAP 
Statistical Analysis Plan 
SARS 
Severe acute respiratory syndrome 
SpO2 
Peripheral capillary oxygen saturation  
SUSAR 
Suspected Unexpected Serious Adverse Reaction 
TB 
Tuberculosis 
TGF 
Transforming growth factor 
TNF 
Tumor necrosis factor 
WCBP 
Woman/women of childbearing potential 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 24 of 74 
Version 3.0, 12 May 2021 
1 
INTRODUCTION AND BACKGROUND INFORMATION  
FP-025 is a novel, non-hydroxamate, selective small molecule inhibitor of matrix 
metalloproteinase (MMP)-12, a protease implicated in many inflammatory and fibrotic diseases in 
the lung and other tissues. FP-025 is being evaluated as a treatment for adult patients with severe 
to critical coronavirus (CoV) disease 2019 (COVID-19) and associated acute respiratory distress 
syndrome (ARDS). 
1.1 
Coronavirus Disease 2019 
CoV are widely found in nature and possess the largest single-stranded positive-sense ribonucleic 
acid genome known.1 Although CoV are common causes of respiratory infections in humans, most 
of these strains cause mild respiratory symptoms in immunocompetent hosts.1 Three of these 
CoV strains, however, have been observed to be highly pathogenic. The severe acute respiratory 
syndrome (SARS)-CoV-1 and Middle East respiratory syndrome (MERS)-CoV strains of past 
outbreaks led to both severe pneumonia1 and ARDS,2 a frequently fatal condition caused by a viral 
infection-induced elevation of inflammatory cytokines. In December 2019, in Wuhan, China, the 
third highly pathogenic CoV, SARS-CoV-2, emerged in the human population. 3  As of 
08 November 2020, the United States has reported a total of 9,808,411 cases of COVID-19 with 
236,547 deaths from the disease.4 
Symptoms of COVID-19 appear 2 to 14 days after exposure (median of 5 to 7 days) and range 
from mild symptoms to severe illness and death, although approximately 40% to 45% of infected 
humans develop no symptoms.
5  Adults who are immunocompromised (eg, human 
immunodeficiency virus [HIV] infections) or over 65 years of age, particularly those with 
comorbidities such as hypertension, chronic obstructive pulmonary disease (COPD), diabetes, and 
cardiovascular disease, are more susceptible to severe respiratory complications and pneumonia. 
In those who develop severe lower respiratory symptoms, pulmonary infection is typically 
accompanied by a sustained, extreme, inflammatory response or cytokine storm, which can lead 
to severe complications, such as ARDS and subsequent pulmonary edema, systemic hypoxia, 
septic shock, metabolic acidosis, and multiple organ failure.6 
According to the United States Centers for Disease Control (updated 30 June 2020), approximately 
3% to 17% of COVID-19 patients develop ARDS. Among hospitalized patients, that number 
increases to 20% to 40%, and up to 67% to 85% for those admitted to the intensive care unit 
(ICU).7 ARDS is associated with mortality rates of approximately 40%;8 however, mortality from 
COVID-19−induced ARDS is even higher, with reported death rates of at least 50%.9,10 Computed 
tomography (CT) scanning of the lungs of ARDS survivors often demonstrates abnormalities 
similar to those seen in pulmonary fibrosis.11 This is also consistent with findings from patients 
with previous SARS and MERS infections, many of whom exhibited post-viral pulmonary 
fibrosis.12, 13 Although long-term lung fibrosis in recovered COVID-19 patients has not been 
studied in detail due to the recent emergence of the disease, it is reasonable to expect that 
pulmonary fibrosis will be a significant issue in patients recovering from COVID-19. In the 
literature, it was reported that histological features of lung fibrosis were found to relate to the 
duration of ARDS. 14  Potential anti-inflammatory and anti-fibrotic treatments could probably 
benefit COVID-19 patients if given at early onset of ARDS.15 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 25 of 74 
Version 3.0, 12 May 2021 
1.2 
FP-025 
FP-025 is a selective small molecule inhibitor of MMP-12, which is a potential mediator of both 
inflammatory responses and structural remodeling that can occur in patients with 
COVID-19−associated respiratory disease.  
MMP-12 expression and secretion are tightly regulated and limited to a few cell types. Its 
expression is increased in various disease states. Key functions of MMP-12 include the modulation 
of numerous components of the extracellular matrix, namely elastin and collagen. MMP-12 also 
modulates effector proteins and cells, such as the influx of monocytes and macrophages involved 
in inflammation and fibrosis. 
MMP-12 is mainly produced and secreted by activated macrophages, as well as by pulmonary 
epithelial cells and chondrocytes. As such, MMP-12 is implicated in many inflammatory and 
fibrotic diseases of the lung. For instance, Rhinovirus-induced interferon (IFN)-γ stimulates 
MMP-12 expression, particularly in cluster of differentiation (CD)11b+/CD11c+ macrophages, 
which may degrade alveolar walls and lead to emphysema progression in mice.16 MMP-12 is also 
upregulated after the induction of an asthmatic reaction using allergens.17 MMP-12 inhibition is 
associated with protective effects on both emphysema and small airway remodeling in animal 
models. 18  In COPD patients, the expression of pulmonary MMP-12 in bronchial tissues, 
bronchoalveolar lavage (BAL) cells (macrophages), and fluids is significantly higher than that of 
normal controls.19 MMP-12 is also implicated in interstitial lung diseases. MMP-12 is involved in 
both the acute and chronic phases of the inflammatory response in granulomatous diseases. 
Reduction in granuloma formation in the MMP-12 knockout mice compared to wild type supports 
a critical role for MMP-12 in granuloma formation.20 MMP-12 gene and protein expression are 
also both increased in BAL samples from patients with sarcoidosis, correlating with disease 
severity.21,22 
Foresee Pharmaceuticals, Co. Ltd. (hereafter, Foresee) is developing a potent and selective 
MMP-12 inhibitor, known as FP-025. FP-025 has shown preclinical efficacy in a 
lipopolysaccharide (LPS)-induced acute lung injury mouse model in reducing inflammatory cells 
in BAL fluid, as well as reducing the bronchial, arteriole, and alveolar damage and lung injury 
induced by LPS. In a bleomycin-induced unilateral lung fibrosis rat model, FP-025 reduced 
fibrosis, reduced bronchial and arterial damage in the lung, and attenuated the level of fibrotic 
biomarkers such as collagen 1, collagen 4, and transforming growth factor (TGF)-β1. FP-025 has 
undergone repeated-dose Good Laboratory Practice (GLP) toxicity studies in 2 species (up to 
28 days of dosing in rats and dogs), as well as GLP safety, pharmacology, and genotoxicity studies. 
In humans, single and multiple ascending dose studies of FP-025 have been conducted in healthy 
human patients, demonstrating dose-proportional and time-independent pharmacokinetics (PK) up 
to 400 mg twice daily (BID) for 7 days. In these studies, FP-025 was safe and well tolerated. 
FP-025 is currently undergoing a house dust mite-induced allergen-challenge study in the 
Netherlands (Study FP02C-18-001). The objective of the study is to test the potential of FP-025 to 
reduce the late allergic response and other inflammatory biomarkers due to the allergen challenge. 
A dose regimen of 400 mg BID for 12 days is being used. At this time, there have been no safety 
issues identified in this ongoing study. All doses have been well tolerated with no deaths or 
treatment-emergent serious adverse events (SAEs). 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 26 of 74 
Version 3.0, 12 May 2021 
1.3 
Rationale 
MMP-12 is upregulated in pulmonary injury and fibrotic conditions. FP-025, a selective and potent 
MMP-12 inhibitor, was shown to have effects in preclinical inflammation and fibrosis models of 
the lung, making it a promising treatment for inflammatory airway diseases. Severe to critical 
COVID-19 with associated ARDS is likely associated with fibrosis and remodeling in the lung. It 
is postulated that FP-025 may potentially avert the lung injury and fibrosis caused by COVID-19 
infections.  
Preclinical and clinical studies suggest that administration of FP-025 in doses of 100 mg to 300 mg 
BID for 28 days in COVID-19 patients should be safe and efficacious. In healthy subjects, FP-025 
has been found to be safe and well tolerated at dosages up to 400 mg BID for 7 days. Efficacy has 
been demonstrated in non-clinical studies, including the LPS-induced acute lung injury study in 
mice, at doses of 10 mg/kg and below, which is lower than the human equivalents of 100 mg and 
300 mg. At those levels, the projected plasma exposure of FP-025 would be lower than the doses 
of 100 and 300 mg. FP-025 is currently being given at 400 mg BID for 12 days in a clinical study 
of patients with asthma. That study is ongoing and remains blinded. The dose level of FP-025 in 
that study is 400 mg BID for 12 days. 
Foresee plans to initiate this study in severe to critical COVID-19 patients with ARDS to test the 
potential of FP-025 in reducing lung injury in these patients. Foresee is proposing a randomized, 
placebo-controlled, double-blind, parallel-designed, 28-day dosing study in adult patients with 
severe to critical COVID-19 with associated ARDS. 
1.4 
Risk/Benefit 
This study will evaluate the efficacy and safety of FP-025 in adult patients with severe to critical 
COVID-19 with associated ARDS. Scientific data suggest that a benefit to the patients may exist 
from participating in the study.  
Preclinical and clinical studies suggest that risks to the patient will be minimal with administration 
of FP-025. In both preclinical species (rat and dog), FP-025 showed a very benign toxicity profile. 
Safety pharmacology studies were conducted in rats to evaluate central nervous system and 
respiratory safety and in dogs to evaluate cardiovascular safety. No treatment-related effects of 
FP-025 were revealed in these studies. In humans, single and multiple ascending dose studies of 
FP-025 have demonstrated that FP-025 is safe and well tolerated. In the ongoing house dust 
mite-induced allergen-challenge study in asthmatic patients, no safety issues have been identified 
to date. All doses have been well tolerated with no deaths or treatment-emergent SAEs.  
Refer to the Investigator’s Brochure for additional information. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 27 of 74 
Version 3.0, 12 May 2021 
2 
STUDY OBJECTIVES 
2.1 
Primary Objectives 
The primary objectives of this study are the following: 
• To evaluate the efficacy of FP-025, compared to placebo, in adult patients with severe to 
critical COVID-19 with associated ARDS, when used with standard of care treatment for 
COVID-19; and 
• To evaluate the safety and tolerability of FP-025 in adult patients with severe to critical 
COVID-19 with associated ARDS. 
2.2 
Secondary Objectives 
The secondary objectives of this study are the following: 
• To evaluate the efficacy of FP-025, compared to placebo, in improving acute COVID-19 
outcomes as measured by the change over time in the National Institute of Allergy and 
Infectious Diseases (NIAID) 8-point ordinal scale for COVID-19 and hospitalization outcomes, 
when used with standard of care treatment for COVID-19; 
• To evaluate the efficacy of FP-025, compared to placebo, in reducing or preventing pulmonary 
fibrosis as determined by quantitative high-resolution, non-contrast CT scan, when used with 
standard of care treatment for COVID-19; 
• To evaluate the effect of FP-025, compared to placebo, on pulmonary function testing, when 
used with standard of care treatment for COVID-19; 
• To evaluate the effect of FP-025, compared to placebo, on renal function in adult patients with 
severe to critical COVID-19 with associated ARDS; and 
• To assess the PK of FP-025 in adult patients with severe to critical COVID-19 with associated 
ARDS. 
2.3 
Exploratory Objective 
The exploratory objective of this study is to evaluate the effect of FP-025, compared to placebo, 
on inflammatory and fibrotic biomarkers in blood when used with standard of care treatment for 
COVID-19. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 28 of 74 
Version 3.0, 12 May 2021 
3 
STUDY DESCRIPTION 
3.1 
Summary of Study Design 
This is a Phase 2/3, randomized, double-blind, placebo-controlled, multicenter study to evaluate 
the efficacy and safety of FP-025 in adult patients with severe to critical COVID-19 with 
associated ARDS. The patients in each phase (Phase 2 and Phase 3) will be analyzed separately. 
Each phase will consist of a Screening Visit, Treatment Period, and Follow-Up Period for a total 
study duration of approximately 60 days. 
3.1.1 
Phase 2 
After eligibility is confirmed, approximately 99 patients will be randomized in a 1:1:1 ratio to 
receive FP-025 100 mg BID, FP-025 300 mg BID, or placebo BID for 28 days. During Phase 2, 
randomized patients will be stratified by the use of invasive mechanical ventilation at the time of 
randomization (yes or no). At least one-third of patients should be on invasive mechanical 
ventilation to ensure that treatment benefits can be assessed for patients at different severity levels. 
Patients with Grade 3 to Grade 4 heart failure, Stage 3 or greater COPD, persistent asthma, and 
mild liver disease (ie, Child-Pugh Class A) will not be excluded from the study. The independent 
Data Monitoring Committee (iDMC) will independently monitor safety of the entire population 
and in different subgroups and may make recommendations as it deems appropriate. During 
Phase 2, no limitation in enrollment of subgroups is expected, unless clear safety signals arise in 
those subgroups during iDMC reviews. 
The reason for hospital admission, the standard of care followed for each patient and center, and 
whether any care decisions were based on resource limitations will be clearly documented for all 
patients beginning on Day 1 (Visit 2). All patients will be allowed to receive standard of care 
and/or emergency use authorization (EUA) medications and treatment for COVID-19; however, 
the study drug should be discontinued for other non-standard of care concomitant medications 
used with the intent of directly treating COVID-19 unless there is prior Medical Monitor or 
Sponsor approval for the patient to remain on the study drug. If the use of concomitant medications 
necessitates study drug discontinuation, the patient should be encouraged to remain in the study 
and to follow-up for key study visits (Day 28 and Day 60) but will not be required to attend every 
study visit. If the patient withdraws, he/she should complete the Early Termination Visit. 
Standard of care procedures for mechanical ventilation (eg, low tidal volume protective 
mechanical ventilation) and standard of care procedures for weaning from mechanical ventilation 
will be followed. The clinical criteria for weaning readiness testing and discontinuation from 
mechanical ventilation are described in Appendix D.  
Study drug administration will begin on Day 1 (Visit 2) following randomization. All patients will 
receive standard of care and/or EUA treatment for COVID-19 in addition to the study drug. 
Patients will continue study drug treatment BID through Day 27 and take 1 dose on Day 28. If a 
patient is discharged from the hospital prior to Day 28, he/she will continue treatment as an 
outpatient at home with his/her assigned treatment (FP-025 100 mg BID, FP-025 300 mg BID, or 
placebo BID) until Day 28. Dosing instructions will be provided prior to discharge. Although 
treatment will be identical for inpatients and outpatients, patients discharged from the hospital will 
follow a different Schedule of Procedures, characterized by telemedicine (or telephone, if sites 
and/or patients do not have video capability) visits. The End of Treatment (EOT) Visit on Day 28 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 29 of 74 
Version 3.0, 12 May 2021 
will be identical for all patients (with the exception of the arterial oxygen partial pressure 
[PaO2]/fractional inspired oxygen [FiO2] ratio, performed only in patients on invasive or 
non-invasive ventilation) and will include a high-resolution, non-contrast CT scan, in addition to 
other assessments. 
After treatment is completed, all patients will undergo 2 follow-up assessments during the 
Follow-Up Period. The first follow-up will be a telephone visit on Day 45 to assess concomitant 
medications, adverse events (AEs), and the NIAID 8-point ordinal scale for COVID-19 and 
hospitalization outcomes score. The second follow-up will be an in-person visit on Day 60 and 
will include a high-resolution, non-contrast CT scan and pulmonary function tests, in addition to 
other assessments. 
An iDMC will convene to oversee safety and efficacy assessments during and after the Phase 2 
study. The first iDMC meeting will occur after approximately 10 to 15 patients have been enrolled. 
The second iDMC meeting will occur after approximately 50% to 60% of patients have been 
enrolled. No formal statistical testing will be conducted. In addition, when all patients in the 
Phase 2 study have completed the EOT Visit on Day 28, a primary analysis will be conducted by 
an independent statistician and reviewed by the iDMC. 
3.1.2 
Phase 3 
Based on the results of the primary analysis of Phase 2, 1 optimal dose will be selected to carry 
into Phase 3. Once the optimal dose has been selected, the study may proceed to Phase 3. Patients 
will be randomized in a 1:1 ratio to receive FP-025 or placebo for 28 days. Similar procedures will 
be followed as for Phase 2; however, study design (eg, eligibility criteria, sample size number, 
protocol-defined procedures, and timing of procedures) or dosing may be changed based on iDMC 
recommendations after data from the primary analysis in Phase 2 becomes available. If the iDMC 
recommends modification of the protocol, and the Sponsor is in agreement, the protocol will be 
amended and submitted to regulatory authorities and Institutional Review Boards (IRBs) for 
approval. An interim analysis will be conducted after approximately 70% (213 out of 304) of the 
randomized patients have completed the EOT Visit on Day 28 or have discontinued early, but 
would have reached Day 28 had they remained in the study, to assess for safety, early futility, and 
potential sample size recalculation. 
3.2 
Study Indication 
The indication for this study is the treatment of patients with severe to critical COVID-19 with 
associated ARDS. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 30 of 74 
Version 3.0, 12 May 2021 
4 
SELECTION AND WITHDRAWAL OF PATIENTS  
The population for this study will include male or female patients ≥18 years with a diagnosis of 
severe to critical COVID-19 with associated ARDS. 
4.1 
Inclusion Criteria 
Patients who meet all of the following criteria will be eligible to participate in the study: 
1. Is willing to provide informed consent (or has a legally authorized representative [LAR] 
willing to provide informed consent) and is willing and able (or has an LAR willing and able) 
to comply with the protocol-required therapy, monitoring, and follow-up; 
2. Is a male or female aged ≥18 years; 
3. Has a COVID-19 diagnosis confirmed by a documented, positive SARS-CoV-2 reverse 
transcriptase polymerase chain reaction test (or equivalent test) immediately prior to or during 
the current hospitalization; 
4. Is hospitalized with severe to critical COVID-19 within a 72-hour period prior to the Screening 
Visit and meeting the following characteristics: 
o Diagnosed with ARDS based on the Berlin criteria as follows: 
 Respiratory symptoms developed within 1 week of a known clinical insult or new or 
worsening respiratory symptoms developed during the past week; 
 Chest radiograph or computed tomography scan shows bilateral opacities not fully 
explained by pleural effusions, lobar or lung collapse, or pulmonary nodules; and 
 Respiratory failure is not fully explained by cardiac failure or fluid overload; and 
o Requiring at least 1 of the following: 
 Endotracheal intubation and mechanical ventilation;  
 Oxygen delivered by high flow nasal cannula (heated, humidified oxygen delivered via 
reinforced nasal cannula at flow rates >20 L/minute with a fraction of delivered 
oxygen ≥0.5);  
 Non-invasive positive pressure ventilation; or  
 Clinical diagnosis of respiratory failure (ie, the clinical need for 1 of the preceding 
therapies, but preceding therapies are unable to be administered in the setting of 
resource limitations); 
5. If female, is post-menopausal for at least 1 year, surgically sterile (documented by medical 
record), or a woman of childbearing potential (WCBP) who agrees to use a highly effective 
method of birth control (ie, method with a failure rate <1% per year) from enrollment until 
30 days following the last dose of study drug. Highly effective methods of birth control are 
defined as follows: complete sexual abstinence, intrauterine device, intrauterine 
hormone-releasing system, progestogen-only hormonal contraception (implant, injectable, or 
oral), and combined (estrogen and progestogen) contraception (oral, intravaginal, or 
transdermal); 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 31 of 74 
Version 3.0, 12 May 2021 
6. If a WCBP, must have a negative serum human chorionic gonadotropin (hCG) pregnancy test 
at the Screening Visit (or have a negative historical serum hCG within the 24 hours before the 
Screening Visit) and must agree to monthly urine pregnancy tests during the study; and 
7. If male, must be surgically sterile for at least 1 year prior to the Screening Visit (documented 
by medical record), or must agree to use a double barrier approach (eg, condoms with 
spermicide) during sexual intercourse between the Screening Visit and at least 90 days after 
administration of the last dose of study drug. Male patients must ensure that non-pregnant 
female partners of childbearing potential comply with the contraception requirements in 
Inclusion Criterion 5. 
4.2 
Exclusion Criteria 
Patients who meet any of the following criteria will be excluded from participation in the study: 
1. Is not expected to survive more than 24 hours; 
2. Is on extracorporeal membrane oxygenation (ECMO) at the Screening Visit; 
3. Has an underlying clinical condition where, in the opinion of the Investigator, it would be 
extremely unlikely that the patient would come off ventilation (eg, motor neuron disease, 
Duchenne muscular dystrophy, or rapidly progressive pulmonary fibrosis); 
4. Has a known history of idiopathic pulmonary fibrosis or interstitial lung disease as defined by 
the American Thoracic Society 2018 guidelines;23 
5. Has known active tuberculosis (TB), a history of incompletely treated TB, and/or suspected or 
known extrapulmonary TB; 
6. Has Child-Pugh Class B or C active liver disease or an alanine aminotransferase or aspartate 
aminotransferase level >4 × the upper limit of normal at the Screening Visit; 
7. Has moderate to severe renal insufficiency, defined as an estimated glomerular filtration 
rate (eGFR) ≤30 mL/min/1.73 m2, at the Screening Visit or requires hemodialysis; 
8. Has a malignant tumor (excluding a malignant tumor cured with no recurrence in the past 
5 years, completely resected basal cell and squamous cell carcinoma of skin, and/or completely 
resected carcinoma in situ of any type); 
9. Has an uncontrolled systemic or local autoimmune or inflammatory disease besides COVID-19; 
10. Has evidence of an active concurrent non-COVID-19 pneumonia that requires additional 
antimicrobial treatment at the time of the Screening Visit and is caused by a known or 
suspected bacterial pathogen, respiratory syncytial virus (RSV), influenza virus, SARS-CoV-1, 
MERS-CoV, aspergillus, mucormycosis-causing fungi, or other pulmonary pathogen(s);  
Note: If a viral respiratory panel has not been collected within the 24 hours prior to the 
Screening Visit, a viral respiratory panel will be administered at the Screening Visit to 
determine eligibility. At a minimum, the panel will evaluate for RSV, influenza A, and 
influenza B. 
11. Has received any other investigational therapeutic products within 4 weeks or 5 half-lives, 
whichever is longer, prior to randomization; 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 32 of 74 
Version 3.0, 12 May 2021 
12. Has a known history of HIV, hepatitis B, or hepatitis C infection; 
13. Has a known serious allergic reaction or hypersensitivity to any components of FP-025; 
14. Is pregnant or breastfeeding; 
15. Has a history of drug or alcohol abuse within the past 2 years; 
16. Is currently on another systemic immunomodulatory therapy that is not considered standard of 
care treatment for COVID-19 (eg, calcineurin inhibitor, hydroxychloroquine, anti-cytokine 
therapy, or Janus kinase inhibitor); 
Note: Corticosteroids, including dexamethasone, in doses used for standard of care treatment 
for COVID-19 are allowed.  
Note: Corticosteroids that are being used for other indications are also allowed as long as the 
daily prednisone (or other corticosteroid equivalent) dose is ≤10 mg. Inhaled corticosteroids 
and nasal corticosteroids are also acceptable.  
Note: As therapies for COVID-19 are rapidly evolving, other medications that may be 
considered standard of care can be considered with prior approval from the Sponsor or Medical 
Monitor. 
17. Is currently on a strong cytochrome P450 inducer or inhibitor (see Appendix E); or  
18. Has any other condition that, in the opinion of the Investigator, could interfere with (or for 
which the treatment might interfere with) the conduct of the study or interpretation of the study 
results or that would place the patient at undue risk by participating in the study. 
4.3 
Stopping Criteria  
All AEs should be considered possibly related to study drug unless clearly unrelated or if there is 
a clear etiology other than study drug such as a pre-existing medical condition, an underlying 
disease, or a concomitant medication. The decision to have an associated pause in enrollment will 
be made by the chairperson of the iDMC (with input from the Medical Monitor). The iDMC will 
oversee the safety and tolerability of FP-025 during the study and determine if it is acceptable to 
continue, as described in Section 9.2.4. However, safety and tolerability data will be reviewed on 
an ongoing basis by the Medical Monitor and stopping rules will be applicable starting with dosing 
of the first patient. 
4.3.1 
Criteria for Potential Interruption or Discontinuation of Study Drug in Individual 
Patients 
In the event that any of the following is encountered, the Investigator, Sponsor, or Medical Monitor 
may choose to interrupt the study drug (in consultation with the Medical Monitor) or discontinue 
a patient from the study drug (but continue to follow the patient for safety and key efficacy 
endpoints):  
• ≥Grade 3 (Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) AE or 
clinically significant laboratory abnormality considered related to study drug; 
Note: All ≥Grade 3 (CTCAE) laboratory abnormalities should be confirmed with a repeat test 
within 24 hours to confirm the abnormality.  

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 33 of 74 
Version 3.0, 12 May 2021 
• Severe anaphylactic reaction, including bronchospasm; or 
• Requirement for a prohibited concomitant medication (eg, non-standard of care concomitant 
medications for COVID-19). 
For any patient who prematurely discontinues from study drug, the reason and date of 
discontinuation will be documented in the electronic case report form (eCRF) and the patient 
should continue to complete all safety assessments at subsequent study visits. 
4.3.2 
Criteria for Potential Study Termination 
In the event that any of the following is encountered, the iDMC will convene to determine if the 
study must stop enrollment and/or to recommend modification to the protocol (ie, decrease or 
change the dose of study drug, modify dosing schedule, or terminate the study, as described in the 
iDMC Charter): 
• ≥Grade 4 (CTCAE version 5.0) reaction considered related to study drug; 
• ≥3 patients are discontinued from treatment for safety reasons; or 
• ≥3 patients experience similar SAEs or Grade 3 (CTCAE version 5.0) AEs regardless of 
relatedness to study drug. 
Note: All ≥Grade 3 (CTCAE) laboratory abnormalities should be confirmed with a repeat test 
within 24 hours to confirm the abnormality. 
The following will not be considered as criteria for study termination: 
• Grade 3 nausea if resolves to ≤Grade 1 within 72 hours; 
• Grade 3 fatigue, malaise, or insomnia if resolves to ≤Grade 1 within 72 hours; and 
• ≤Grade 4 isolated electrolyte abnormalities that resolve with or without intervention to 
≤Grade 1 within 72 hours. 
4.4 
Withdrawal Criteria 
Participation of a patient in this study may be discontinued for any of the following reasons: 
• Withdrawal of consent or request for discontinuation from the study for any reason; and 
• Loss to follow-up. 
If a patient withdraws prematurely from the study due to the above criteria or any other reason, 
study staff should make every effort to complete the full panel of assessments scheduled for the 
Early Termination Visit. The reason for patient withdrawal must be documented in the eCRF. 
In the case of patients lost to follow-up, attempts to contact the patient must be made and 
documented in the patient’s medical records. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 34 of 74 
Version 3.0, 12 May 2021 
Study drug treatment may be discontinued (although the patient should be encouraged to remain 
in the study and to follow-up for key study visits) for any of the following reasons: 
• Occurrence of any medical condition or circumstance that exposes the patient to substantial 
risk and/or does not allow the patient to adhere to the requirements of the protocol; 
• Any SAE, clinically significant AE, severe laboratory abnormality, intercurrent illness, or 
other medical condition which indicates to the Investigator that continued participation is not 
in the best interest of the patient; 
Note: Patients who discontinue study drug for safety or tolerability reasons will not be replaced.  
• Pregnancy; or 
• Patient failure to comply with protocol requirements or study-related procedures. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 35 of 74 
Version 3.0, 12 May 2021 
5 
STUDY TREATMENTS 
5.1 
Treatment Groups 
During Phase 2, patients will be randomized in a 1:1:1 ratio to receive FP-025 100 mg BID, 
FP-025 300 mg BID, or placebo BID for 28 days, starting on Day 1 (Visit 2). Patients in each dose 
group will receive a total of 6 capsules during each dosing session as follows: 
• FP-025 100 mg BID: Two 50 mg capsules and 4 placebo capsules; 
• FP-025 300 mg BID: Six 50 mg capsules; and 
• Placebo: 6 placebo capsules. 
Based on the results of the primary analysis of Phase 2, 1 optimal dose will be selected to carry 
into Phase 3, and patients will be randomized in a 1:1 ratio to receive FP-025 or placebo for 28 days. 
No dose adjustments will be performed for renal impairment. 
5.2 
Rationale for Dosing 
Preclinical and clinical studies suggest that administration of FP-025 in doses of 100 mg to 300 mg 
BID for 28 days in COVID-19 patients should be safe and efficacious. In healthy subjects, FP-025 
has been found to be safe and well tolerated at dosages up to 400 mg BID for 7 days. Efficacy has 
been demonstrated in non-clinical studies, including the LPS-induced acute lung injury study in 
mice, at doses of 10 mg/kg and below, which is lower than the human equivalents of 100 mg and 
300 mg. At those levels, the projected plasma exposure of FP-025 would be lower than the doses 
of 100 and 300 mg. A clinical study in patients with asthma is ongoing and remains blinded. The 
dose level of FP-025 in that study is 400 mg BID for 12 days.  
5.3 
Randomization and Blinding 
During Phase 2, patients will be randomized in a 1:1:1 ratio to receive FP-025 100 mg BID, 
FP-025 300 mg BID, or placebo BID for 28 days. Patients in each dose group will receive a total 
of 6 capsules during each dosing session as described in Section 5.1 in order to maintain blinding. 
Randomized patients will be stratified by the use of invasive mechanical ventilation at the time of 
randomization (yes or no). Patients, Investigators, and study personnel involved in the 
administration and assessment of the study drug will be blinded to the patient treatment 
assignments throughout the study. 
5.4 
Breaking the Blind 
Unblinding by request of an Investigator should occur only in the event of an emergency or AE 
for which it is necessary to know the study drug to determine an appropriate course of therapy for 
the patient. If the Investigator must identify the treatment assignment of an individual patient, the 
Investigator or qualified designee should request the treatment assignment from the centralized 
randomization system. The Investigator is advised not to reveal the study drug assignment to other 
centers or Sponsor personnel.  
Prior to unblinding, and if the situation allows, the Investigator should consult with the Medical 
Monitor. If this is impractical, the Investigator must notify the Medical Monitor as soon as possible, 
without revealing the treatment assignment of the unblinded patient. The Investigator must 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 36 of 74 
Version 3.0, 12 May 2021 
document the patient identification and the date and time for breaking the blind and must clearly 
explain the reasons for breaking the blind.  
Medically necessary care should not be delayed for unblinding information (ie, the Investigator 
should treat the patient based on the patient’s signs/symptoms without waiting for the unblinding 
process to be completed).  
Patients who are unblinded and discontinue study drug but are not withdrawn from the study 
should continue to complete all safety assessments at subsequent study visits. 
5.5 
Drug Supplies 
5.5.1 
Formulation and Packaging 
FP-025 is supplied as an oral capsule (amorphous solid dispersion-in-capsule) at a dose strength 
of 50 mg per capsule. 
Foresee will supply sufficient quantities of study drug (FP-025 and matching placebo) to allow for 
completion of the study. The lot numbers will be recorded in the final clinical study report. 
5.5.2 
Study Drug Preparation and Dispensing 
The study drug (FP-025 and matching placebo) will be dispensed by the pharmacist or qualified 
designee. 
5.5.3 
Study Drug Administration 
The study drug (FP-025 and matching placebo) will be administered orally as capsules or via a 
polyvinyl chloride nasogastric tube (by opening up the capsules and delivering as a suspension in 
orange juice). Capsules can also be opened and added to orange juice to drink. During Phase 2, 
each patient will receive either FP-025 (100 mg or 300 mg) or placebo BID for 28 days. Based on 
the results of the primary analysis of Phase 2, 1 optimal dose will be selected to carry into Phase 3, 
and patients will be randomized in a 1:1 ratio to receive FP-025 or placebo for 28 days. 
5.5.4 
Treatment Compliance 
To ensure treatment compliance, all inpatient doses will be administered by center staff. 
For outpatients, treatment compliance will be assessed by pill counts. Center staff will counsel 
patients on the importance of adhering to the study drug administration schedule prior to hospital 
discharge. At the next inpatient visit on Day 28, center staff will count the number of capsules left 
in the bottle and compare that to the number of capsules the patient was given at hospital discharge.  
The exact time of study drug administration and the volume of study drug administered will be 
recorded in the eCRF. 
5.5.5 
Storage and Accountability 
At the center, FP-025 will be stored at room temperature (ie, 20°C to 25°C [68°F to 77°F]) under 
secure conditions. 
The pharmacist (or designee) will acknowledge receipt of all shipments of the study drug and 
maintain an inventory. The study drugs must be kept in a locked area with restricted access and 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 37 of 74 
Version 3.0, 12 May 2021 
stored and handled in accordance with the manufacturer's instructions. The pharmacist (or designee) 
will also keep accurate records of the quantities of the study drugs dispensed and used by each 
patient. The clinical research associate (CRA) will periodically check the supplies of study drugs 
held by the pharmacist to verify accountability of all study drugs used. 
At the conclusion of the study, the CRA will account for all used and unused study drug. After 
completion of the study, or if it is prematurely terminated, all unused materials will be returned to 
the Sponsor or a delegate. Additional information can be found in the Pharmacy Manual. 
5.6 
Prior and Concomitant Medications and/or Procedures 
5.6.1 
Excluded Medications and/or Procedures 
The following medications, taken within 4 weeks or 5 half-lives, whichever is longer, are 
prohibited:  
• Systemic immunomodulatory therapy that is not considered standard of care treatment for 
COVID-19 (eg, calcineurin inhibitors, hydroxychloroquine, anti-cytokine therapies, or Janus 
kinase inhibitors);  
Note: Corticosteroids, including dexamethasone, in doses used for standard of care treatment 
for COVID-19 are allowed. 
Note: Corticosteroids that are being used for other indications are also allowed as long as the 
daily prednisone (or other corticosteroid equivalent) dose is ≤10 mg. Inhaled corticosteroids 
and nasal corticosteroids are also acceptable.  
Note: As therapies for COVID-19 are rapidly evolving, other medications that may be 
considered standard of care can be considered with prior approval from the Sponsor or Medical 
Monitor. 
• Strong cytochrome P450 inducers or inhibitors as listed in Appendix E; or  
• Any other investigational therapeutic products. 
5.6.2 
Documentation of Prior and Concomitant Medication Use 
Any investigational and off-label therapies for COVID-19−related infections for each patient 
(eg, hydroxychloroquine or interleukin [IL]-6 inhibitors), along with the time, dose, and duration 
of their administration, must be recorded. All patients will be allowed to receive standard of care 
and/or EUA medications and treatment for COVID-19; however, the study drug should be 
discontinued for other non-standard of care concomitant medications used with the intent of 
directly treating COVID-19 unless there is prior Medical Monitor or Sponsor approval for the 
patient to remain on the study drug. If the use of concomitant medications necessitates study drug 
discontinuation, the patient should be encouraged to remain in the study and to follow-up for key 
study visits (Day 28 and Day 60) but will not be required to attend every study visit. If the patient 
withdraws, he/she should complete the Early Termination Visit. 
Any treatment given in addition to the study drug during the study is regarded as a concomitant 
medication and must be recorded on the appropriate eCRF. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 38 of 74 
Version 3.0, 12 May 2021 
Any relevant medications received in the 14 days prior to study drug administration must be 
recorded on the appropriate eCRF, along with the reason for use, dates of administration, and 
dosages. 
Concomitant medications should be kept to a minimum during the study. However, if these are 
considered necessary for the patient’s welfare and are unlikely to interfere with the study drug, 
they may be given at the discretion of the Investigator and recorded in the patient’s source 
documents and the eCRF. 
Any care decisions that are made due to resource limitation (eg, ventilation not available) must be 
documented.  
Data surrounding major changes in background therapy will be collected. The standard of care that 
is followed for each patient and center must be recorded. If standard of care therapies are not able 
to be delivered due to resource limitations, this should also be recorded. 
Any reasons for discontinuation of ventilation must be recorded on the appropriate eCRF, 
including all data related to clinical decision making that guides removal from mechanical 
ventilation in relation to clinical deterioration or lack of clinical response. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 39 of 74 
Version 3.0, 12 May 2021 
6 
STUDY PROCEDURES 
Study procedures will follow the Schedule of Procedures in Appendix A. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 40 of 74 
Version 3.0, 12 May 2021 
7 
EFFICACY AND PHARMACOKINETIC ASSESSMENTS 
7.1 
Efficacy and Pharmacokinetic Endpoints 
For all endpoints defined by events, the time points are defined as the number of days after 
randomization.  
7.1.1 
Primary Efficacy Endpoint 
The primary efficacy endpoint is the proportion of patients alive and not requiring non-invasive or 
invasive ventilation (ie, not receiving high-flow nasal cannula, non-invasive positive pressure 
ventilation, invasive mechanical ventilation, or ECMO) at Day 28, with each dose (Phase 2) or the 
optimal dose (Phase 3) of FP-025 compared to placebo. 
7.1.2 
Key Secondary Efficacy Endpoints 
The key secondary efficacy endpoints include the following, with each dose (Phase 2) or the 
optimal dose (Phase 3) of FP-025 compared to placebo: 
• Proportion of patients on invasive mechanical ventilation at Day 28; 
• Proportion of patients alive at Day 28; 
• Proportion of patients alive and not requiring non-invasive or invasive ventilation (ie, not 
receiving high-flow nasal cannula, non-invasive positive pressure ventilation, invasive 
mechanical ventilation, or ECMO) at Day 60; 
• Proportion of patients on invasive mechanical ventilation at Day 60; and 
• Proportion of patients alive at Day 60. 
7.1.3 
Other Secondary Efficacy Endpoints 
The other secondary efficacy endpoints include the following, with each dose (Phase 2) or the 
optimal dose (Phase 3) of FP-025 compared to placebo: 
• Quantitative assessment of lung fibrosis at Day 28 and at Day 60 using high-resolution, 
non-contrast CT scan; 
• Proportion of patients who were randomized on invasive mechanical ventilation who are free 
of invasive mechanical ventilation at Day 28 and at Day 60; 
• Number of ventilator-free days (ie, days free of invasive mechanical ventilation) at Day 28 and 
at Day 60; 
• Number of ICU-free days at Day 28 and at Day 60; 
• Number of days in the hospital at Day 28 and at Day 60; 
• Change from baseline in peripheral capillary oxygen saturation (SpO2) at Day 28 and at Day 60; 
• Change from baseline in PaO2/FiO2 ratio at Day 28 and at Day 60 (patients on invasive or 
non-invasive ventilation only); 
• Proportion of patients alive and not hospitalized at Day 28 and at Day 60; 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 41 of 74 
Version 3.0, 12 May 2021 
• Proportion of patients with disease progression (defined as a ≥2-point decrease in the NIAID 
8-point ordinal scale score or death) at Day 28 and at Day 60; 
• Proportion of patients who improve by ≥2 points on the NIAID 8-point ordinal scale scores at 
Day 28 and proportion of patients who improve by ≥2 points at Day 60; 
• Pulmonary function at Day 28 (if possible based on the patient’s clinical condition per the 
judgment of the Investigator) and at Day 60 (all patients) based on the following scores: 
o Forced vital capacity (FVC); 
o Forced expiratory volume in 1 second (FEV1); 
o FEV1/FVC ratios; and 
o Diffusing capacity of the lungs for carbon monoxide; and 
• Change from baseline in eGFR, blood urea nitrogen, and serum creatinine at Day 28 and 
Day 60. 
7.1.4 
Exploratory Endpoints 
Exploratory endpoints will include the change from baseline (pre-dose on Day 1) in biomarkers 
related to pulmonary inflammation, fibrosis and/or lung injury at Day 7, Day 14, Day 28, and 
Day 60, including but not limited to the following, with each dose (Phase 2) or the optimal dose 
(Phase 3) of FP-025 compared to placebo:  
• MMP-12, MMP-7, and MMP-9; 
• Transforming growth factor-β; 
• Connective tissue growth factor;  
• C-reactive protein (CRP); 
• Cytokines (IFN-γ, tumor necrosis factor [TNF]-α, IL-6, IL-1β, and C-C motif chemokine 
ligand 2 [monocyte chemoattractant protein-1]);  
• Ferritin; 
• Released N-terminal pro-peptide of type III collagen; 
• Internal epitope in the 7S domain of type IV collagen; 
• C-terminal of released C5 domain of type VI collagen α3 chain (endotrophin); 
• Neo-epitope of MMP-2, 9, and 13-mediated degradation of type I collagen; 
• Neo-epitope of MMP-2, 9, and 12-mediated degradation of type IV collagen; 
• Neo-epitope of MMP-2-mediated degradation of type VI collagen; 
• Neo-epitope of MMP-1 and 8-mediated degradation of CRP; and 
• Neo-epitope of plasmin-mediated degradation of cross-linked fibrin. 
Additional biomarkers not listed here may be evaluated at a future date. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 42 of 74 
Version 3.0, 12 May 2021 
7.1.5 
Pharmacokinetic Endpoint 
The PK endpoint is the plasma exposure of FP-025 at each dose level. Sampling times will be as 
follows: 
• Day 1 (Visit 2): pre-dose, 1 hour (±10 minutes), 3 hours (±10 minutes), and 8 hours 
(±10 minutes) post the first morning dose of study drug; 
Note: If the patient is randomized in the afternoon on Day 1 (Visit 2), this will be performed 
after the morning dose of study drug on Day 2. 
• Day 4, Day 7, Day 14, and Day 21: within 1 hour (±10 minutes) prior to the morning dose; and 
• Day 28: within 1 hour (±10 minutes) prior to the morning dose and 1 hour (±10 minutes) 
post-morning dose. 
7.2 
Efficacy Assessments 
7.2.1 
Arterial Oxygen Partial Pressure/Fractional Inspired Oxygen Ratio 
A PaO2, obtained via arterial blood gas will be used to calculate the PaO2/FiO2 ratio, only in 
patients on invasive or non-invasive ventilation. 
7.2.2 
Pulmonary Function Tests 
Pulmonary function tests (PFTs) will be performed at the times indicated in Appendix A. PFTs 
will include measurement of FVC, FEV1, FEV1/FVC ratio, and diffusing capacity of the lungs for 
carbon monoxide. 
7.2.3 
Computed Tomography Scan 
A high-resolution, non-contrast CT scan will be performed at the times indicated in Appendix A 
to assess for lung fibrosis. The CT scan will be acquired with a single acquisition of reduced dose 
(ie, 6 mSv total). A chest radiograph may be substituted for the high-resolution, non-contrast 
CT scan at the Screening Visit only for study eligibility. 
7.2.4 
Inflammatory and Fibrotic Biomarker Analysis 
Biomarker analyses will be performed at the times indicated in Appendix A. Biomarkers include, 
but are not limited to, assessments of MMP-12, MMP-7, MMP-9, TGF-β, connective tissue growth 
factor, CRP, cytokines (IFN-γ, TNF-α, IL-6, IL-1β, and C-C motif chemokine ligand 2 [monocyte 
chemoattractant protein-1]), ferritin levels, released N-terminal pro-peptide of type III collagen, 
internal epitope in the 7S domain of type IV collagen, C-terminal of released C5 domain of type VI 
collagen α3 chain (endotrophin), neo-epitope of MMP-2, 9, and 13-mediated degradation of type I 
collagen, neo-epitope of MMP-2, 9, and 12-mediated degradation of type IV collagen, neo-epitope 
of MMP-2-mediated degradation of type VI collagen, neo-epitope of MMP-1 and 8-mediated 
degradation of CRP, and neo-epitope of plasmin-mediated degradation of cross-linked fibrin in 
blood.  
Blood will be collected from patients that have consented (or whose LAR has consented) to the 
procedure. The blood samples will be collected per the laboratory manual instructions and 
analyzed. Samples may be stored at the central laboratory for future analyses. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 43 of 74 
Version 3.0, 12 May 2021 
7.2.5 
National Institute of Allergy and Infectious Diseases 8-Point Ordinal Scale 
The NIAID 8-point ordinal scale score will be assessed at the times indicated in Appendix A. The 
NIAID 8-point ordinal scale is described in detail in Appendix C. 
7.3 
Other Assessments 
7.3.1 
Severe Acute Respiratory Syndrome Coronavirus-2 Testing  
SARS-CoV-2 testing may be performed at the Screening Visit. The patient must have a 
documented, laboratory-confirmed SARS-CoV-2 infection as determined by reverse transcriptase 
polymerase chain reaction (or an equivalent test) immediately prior to or during the current 
hospitalization to be included in the study. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 44 of 74 
Version 3.0, 12 May 2021 
8 
SAFETY ASSESSMENTS 
8.1 
Adverse Events 
An AE is defined as any untoward medical occurrence in a clinical investigation patient 
administered a pharmaceutical product, which does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and/or unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of an 
investigational medicinal product, whether or not related to the investigational medicinal product. 
All AEs, including observed or volunteered problems, complaints, or symptoms, are to be recorded 
on the appropriate eCRF.  
AEs will be monitored and recorded from the time of the first dose of study drug (Day 1 [Visit 2]) 
until the end of the study (Day 60). All events occurring prior to the first dose of study drug will 
be recorded as medical history. Patients should be instructed to report any AE that they experience 
to the Investigator, whether or not they think the event is due to study treatment. Beginning at 
Day 1 (Visit 2), Investigators should make an assessment for AEs at each visit and record the event 
on the appropriate AE eCRF. 
Wherever possible, a specific disease or syndrome rather than individual associated signs and 
symptoms should be identified by the Investigator and recorded on the eCRF. However, if an 
observed or reported sign or symptom is not considered a component of a specific disease or 
syndrome by the Investigator, it should be recorded as a separate AE on the eCRF. Additionally, 
the condition that led to a medical or surgical procedure (eg, surgery, endoscopy, tooth extraction, 
or transfusion) should be recorded as an AE, not the procedure itself.  
Any medical condition already present prior to the first dose of study drug should be recorded as 
medical history and not be reported as an AE unless the medical condition or signs or symptoms 
present at baseline changes in severity, frequency, or seriousness at any time during the study. In 
this case, it should be reported as an AE. 
Clinically significant abnormal laboratory or other examination (eg, electrocardiogram [ECG]) 
findings that are detected during the study or are present at the Day 1 (Visit 2) and significantly 
worsen during the study should be reported as AEs, as described below. The Investigator will 
exercise his or her medical and scientific judgment in deciding whether an abnormal laboratory 
finding or other abnormal assessment is clinically significant. Clinically significant abnormal 
laboratory values occurring during the study will be followed until repeat tests return to normal, 
stabilize, or are no longer clinically significant. Abnormal test results that are determined to be an 
error should not be reported as an AE. Laboratory abnormalities or other abnormal clinical findings 
(eg, ECG abnormalities) should be reported as an AE if any of the following are applicable: 
• If an intervention is required as a result of the abnormality; 
• If action taken with the study drug is required as a result of the abnormality; or 
• Based on the clinical judgment of the Investigator. 
8.1.1 
Adverse (Drug) Reaction 
All noxious and unintended responses to a medicinal product related to any dose should be 
considered an adverse drug reaction. “Responses” to a medicinal product means that a causal 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 45 of 74 
Version 3.0, 12 May 2021 
relationship between a medicinal product and an AE is at least a reasonable possibility (ie, the 
relationship cannot be ruled out). 
8.1.2 
Unexpected Adverse Drug Reaction 
An Unexpected Adverse Drug Reaction is defined as an adverse reaction, the nature or severity of 
which is not consistent with the current Investigator’s Brochure. 
8.1.3 
Assessment of Adverse Events by the Investigator 
The Investigator will assess the severity (intensity) of each AE as mild, moderate, or severe, and 
will also categorize each AE as to its potential relationship to study drug using the categories of 
yes or no. 
Assessment of severity 
The severity of all AEs should be graded according to the CTCAE Version 5.0. For those AE terms 
not listed in the CTCAE, the following grading system should be used: 
• CTCAE Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated; 
• CTCAE Grade 2: Moderate; minimal local or non-invasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living; 
• CTCAE Grade 3: Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care 
activities of daily living; 
• CTCAE Grade 4: Life threatening consequences; urgent intervention indicated; and 
• CTCAE Grade 5: Death related to the AE. 
Causality assessment 
The relationship of an AE to the administration of the study drug is to be assessed according to the 
following definitions: 
• No (unrelated, not related, unlikely to be related) – The time course between the administration 
of study drug and the occurrence or worsening of the AE rules out a causal relationship and 
another cause (concomitant drugs [including alternative, novel treatments for COVID-19], 
therapies, complications, etc) is suspected; or 
• Yes (possibly, probably, or definitely related) – The time course between the administration of 
study drug and the occurrence or worsening of the AE is consistent with a causal relationship 
and no other cause (concomitant drugs, therapies, complications, etc) can be identified. 
The definition implies a reasonable possibility of a causal relationship between the event and the 
study drug. This means that there are facts (evidence) or arguments to suggest a causal relationship. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 46 of 74 
Version 3.0, 12 May 2021 
The following factors should also be considered: 
• The temporal sequence from study drug administration; 
The event should occur after the study drug is given. The length of time from study drug 
exposure to event should be evaluated in the clinical context of the event. 
• Underlying, concomitant, intercurrent diseases; 
Each report should be evaluated in the context of the natural history and course of the disease 
being treated and any other disease the patient may have. 
• Concomitant drug; 
The other drugs the patient is taking or the treatment the patient receives should be examined 
to determine whether any of them might be recognized to cause the event in question. 
• Known response pattern for this class of study drug; 
Clinical and/or preclinical data may indicate whether a particular response is likely to be a 
class effect. 
• Exposure to physical and/or mental stresses; and 
The exposure to stress might induce adverse changes in the recipient and provide a logical and 
better explanation for the event. 
• The pharmacology and PK of the study drug. 
The known pharmacologic properties (absorption, distribution, metabolism, and excretion) of 
the study drug should be considered. 
8.1.4 
Expected Acute Respiratory Distress Syndrome Events 
As events of progression of the patient’s underlying COVID-19 diagnosis will be captured as 
efficacy endpoints (see Section 7.1), these events should not be reported as AEs or SAEs unless 
considered related to the study drug or a study procedure or if the outcome is fatal during the study 
and within the safety reporting period. Additionally, expected events for ARDS that are perceived 
by the Investigator to occur with reasonable frequency in the day-to-day care of patients with 
ARDS treated in an ICU setting with mechanical ventilation will not be reported as AEs. Examples 
of events that are expected in the course of ARDS include transient hypoxemia, agitation, delirium, 
etc. Such events, which are often the focus of prevention efforts as part of standard ICU care, will 
not be considered reportable AEs unless the event is considered by the Investigator to be associated 
with the study drug or study procedures, is unexpectedly severe or frequent, or is a change of 
severity for an individual patient with ARDS. 
8.2 
Serious Adverse Events 
Any SAE that is ongoing at the end of the study (Day 60) will be followed by the Investigator until 
the SAE has subsided or until the condition(s) becomes chronic in nature, until the patient begins 
alternative treatment for COVID-19, until the condition(s) stabilizes (in the case of persistent 
impairment), or until the patient dies.  

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 47 of 74 
Version 3.0, 12 May 2021 
An AE or adverse reaction is considered serious if, in the view of either the Investigator or Sponsor, 
it results in any of the following outcomes: 
• Death; 
• A life-threatening AE; 
Note: An AE or adverse reaction is considered “life-threatening” if, in view of either the 
Investigator or Sponsor, its occurrence places the patient at immediate risk of death. It does 
not include an event that, had it occurred in a more severe form, might have caused death. 
• Requires hospitalization or prolongation of existing hospitalizations; 
Note: Any hospital admission with at least 1 overnight stay will be considered an inpatient 
hospitalization. An emergency room or urgent care visit without hospital admission will not 
be recorded as an SAE under this criterion, nor will hospitalization for a procedure scheduled 
or planned before signing of informed consent, or elective treatment of a pre-existing condition 
that did not worsen from baseline (ie, Day 1 [Visit 2]). However, unexpected complications 
and/or prolongation of hospitalization that occur during elective surgery should be recorded as 
AEs and assessed for seriousness. Admission to the hospital for social or situational reasons 
(ie, no place to stay, live too far away to come for hospital visits, respite care) will not be 
considered inpatient hospitalizations.  
• A persistent or significant disability/incapacity or substantial disruption of the ability to 
conduct normal life functions; 
• A congenital anomaly/birth defect; or 
• An important medical event. 
Note: Important medical events that do not meet any of the above criteria may be considered 
an SAE when, based upon appropriate medical judgment, they may jeopardize the patient and 
may require medical or surgical intervention to prevent one of the outcomes listed above. 
Examples of such medical events include allergic bronchospasm requiring intensive treatment 
in an emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalizations, or the development of drug dependency. 
As events of progression of the patient’s underlying COVID-19 diagnosis will be captured as 
efficacy endpoints (see Section 7.1), these events should not be reported as SAEs unless 
considered related to the study drug or a study procedure or if the outcome is fatal during the study 
and within the safety reporting period. Examples of events that are expected in the course of ARDS 
are provided above in Section 8.1.4. If the event has a fatal outcome during the timeframe, the 
event of “Progression of COVID-19” must be recorded as an SAE with a fatal outcome.  
8.3 
Serious Adverse Event Reporting − Procedures for Investigators 
Initial reports 
All SAEs occurring from the time of the first dose of study drug until Day 60 (approximately 
30 days following the last dose of study drug) must be reported to Medpace Clinical Safety within 
24 hours of the knowledge of the occurrence. After the 30-day reporting window, any SAE that 
the Investigator considers related to study procedures must be reported to the Medpace Clinical 
Safety or the Sponsor/designee. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 48 of 74 
Version 3.0, 12 May 2021 
To report the SAE, complete the SAE form electronically in the electronic data capture (EDC) 
system for the study. When the form is completed, Medpace Safety personnel will be notified 
electronically by the EDC system and will retrieve the form. If the event meets serious criteria and 
it is not possible to access the EDC system, send an email to Medpace Safety at 
Medpace-safetynotification@medpace.com or call the Medpace SAE reporting line (telephone 
number listed below), and fax/email the completed paper SAE form to Medpace (contact 
information listed in Section 8.6) within 24 hours of awareness. When the EDC system becomes 
available, the SAE information must be entered within 24 hours of the system becoming available. 
Follow-up reports 
The Investigator must continue to follow the patient until the SAE has subsided or until the 
condition(s) becomes chronic in nature, stabilizes (in the case of persistent impairment), or the 
patient dies. 
Within 24 hours of receipt of follow-up information, the Investigator must update the SAE form 
electronically in the EDC system for the study and submit any supporting documentation 
(eg, patient discharge summary or autopsy reports) to Medpace Clinical Safety via fax or email. If 
it is not possible to access the EDC system, refer to the procedures outlined above for initial 
reporting of SAEs.  
8.4 
Pregnancy Reporting 
If a patient becomes pregnant during the study or within the safety follow-up period defined in the 
protocol, the Investigator is to stop dosing with study drug(s) immediately and the patient should 
be withdrawn from the study. Early Termination Visit procedures should be implemented at that 
time.  
A pregnancy is not considered to be an AE or SAE; however, it must be reported to Medpace 
Clinical Safety within 24 hours of knowledge of the event. Medpace Clinical Safety will then 
provide the Investigator/center the Exposure In Utero (EIU) form for completion. The 
Investigator/center must complete the EIU form and fax/email it back to Medpace Clinical Safety.  
If the female partner of a male patient becomes pregnant while the patient is receiving study drug 
or within the safety follow-up period defined in the protocol, the Investigator should notify 
Medpace Clinical Safety as described above.  
The pregnancy should be followed until the outcome of the pregnancy is known, whenever 
possible. Once the outcome of the pregnancy is known, the EIU form should be completed and 
faxed/emailed to Medpace Clinical Safety. If the outcome of the pregnancy meets the criteria for 
immediate classification as an SAE (ie, postpartum complication, spontaneous abortion, stillbirth, 
neonatal death, or congenital anomaly), the Investigator should follow the procedures for reporting 
an SAE. 
8.5 
Expedited Reporting 
The Sponsor/designee will report all relevant information about Suspected Unexpected Serious 
Adverse Reactions (SUSAR) that are fatal or life-threatening as soon as possible to the Food and 
Drug Administration (FDA), and in any case no later than 7 days after knowledge by the 
Sponsor/designee of such a case. Relevant follow-up information will subsequently be 
communicated within an additional 8 days.  

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 49 of 74 
Version 3.0, 12 May 2021 
All other SUSARs will be reported to the FDA as soon as possible but within a maximum of 
15 days of first knowledge by the Sponsor/designee.  
The Sponsor/designee will also report any additional expedited safety reports required in 
accordance with the timelines outlined in country-specific legislation.  
The Sponsor/designee will also inform all Investigators as required per local regulation. 
The requirements above refer to the requirements relating to investigational medicinal product. 
8.6 
Special Situation Reports 
Special situation reports include reports of overdose, misuse, abuse, medication error, and reports 
of adverse reactions associated with product complaints. 
• Overdose: Refers to the administration of a quantity of a medicinal product given per 
administration or cumulatively (accidentally or intentionally), which is above the maximum 
recommended dose according to the protocol. Clinical judgment should always be applied. In 
cases of a discrepancy in the drug accountability, overdose will be established only when it is 
clear that the patient has taken additional dose(s) or the Investigator has reason to suspect that 
the patient has taken additional dose(s); 
• Misuse: Refers to situations where the medicinal product is intentionally and inappropriately 
used not in a way that is not in accordance with the protocol instructions or local prescribing 
information and may be accompanied by harmful physical and/or psychological effects; 
• Abuse: Is defined as persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied by harmful physical or psychological effects; 
• Medication error: Is any unintentional error in the prescribing, dispensing, or administration 
of a medicinal product by a healthcare professional, patient, or consumer, respectively. The 
administration or consumption of the unassigned treatment and administration of an expired 
product are always reportable as medication errors, cases of patients missing doses of study 
drug are not considered reportable as medication error; and 
• Product complaint: Is defined as any written, electronic, or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or 
performance of a drug or device after it is released for distribution. A special situations form 
will only be completed if a complaint is associated with an adverse drug reaction.  
All special situation events as described above must be reported on the Special Situations Report 
form and faxed/emailed to Medpace Clinical Safety (contact information listed below) within 
24 hours of knowledge of the event. All AEs associated with these Special Situation reports should 
be reported as AEs or SAEs as well as recorded on the AE eCRF and/or the SAE report form. 
Details of the symptoms and signs, clinical management, and outcome should be provided, when 
available. 
Safety Contact Information: Medpace Clinical Safety 
Medpace SAE reporting line – USA 
Telephone: +1-800-730-5779, dial 3 or +1-513-579-9911, dial 3 
Fax: +1-866-336-5320 or +1-513-570-5196 
Email: medpace-safetynotification@medpace.com 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 50 of 74 
Version 3.0, 12 May 2021 
8.7 
Safety Endpoints 
The safety endpoints include the following:  
• AEs and SAEs; 
• Clinical laboratory assessments (including clinical chemistry, hematology, and urinalysis); 
• Vital signs; 
• Physical examinations; and 
• 12-lead ECGs. 
8.8 
Clinical Laboratory Assessments 
Samples for blood chemistry and hematology will be obtained as indicated in Appendix A. See 
Appendix B for a complete list of analytes. If any additional laboratory evaluations are performed 
for standard of care, these data should be entered into the eCRF. If a blood chemistry or 
hematology assessment was performed within 24 hours prior to the first dose of study drug, it is 
not necessary to repeat the assessment on Day 1. Effort should be made to obtain blood chemistry 
and hematology at approximately the same time on each day as indicated in Appendix A; however, 
it should not be considered a protocol deviation if this is not possible.  
Samples for urinalysis will be obtained as indicated in Appendix A. See Appendix B for a complete 
list of analytes. 
Screening and eligibility laboratory assessments may be performed at the local laboratory. All 
other laboratory assessments during the study will be assessed by a central laboratory. 
8.9 
Pregnancy Test 
A serum hCG will be performed at the Screening Visit for all WCBP. If performed within 
24 hours before the Screening Visit, a historical serum hCG test can be used. A urine pregnancy 
test will be performed at subsequent visits as indicated in Appendix A. 
8.10 
Vital Signs 
Vital signs will be collected as indicated in Appendix A. Vital signs will include temperature, heart 
rate, respiratory rate, blood pressure, and SpO2. For outpatients, pulse oximeters, thermometers, 
and blood pressure cuffs will be provided for home use. 
8.11 
Electrocardiograms 
ECGs should be performed 2 hours (±30 minutes) after the first study drug administration on 
Day 1 and 2 hours (±30 minutes) after the morning dose on Day 4 and Day 7. ECGs may be 
performed at any time at subsequent visits. ECGs will be collected as indicated in Appendix A. 
Patients should be in a supine position for at least 10 minutes prior to ECG measurement. 
8.12 
Physical Examinations 
A full physical examination will be performed at the Screening Visit, the EOT Visit, and Day 60. 
A full physical examination may include assessments of general condition, skin, 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 51 of 74 
Version 3.0, 12 May 2021 
eyes/ears/nose/mouth/throat, neck/thyroid, chest/lungs, heart, vascular system, lymph nodes, 
abdomen, extremities, nervous systems/reflexes, musculoskeletal system, and spine.  
A brief physical examination or a telemedicine-based physical examination (if the patient and site 
have video capabilities) will be performed at the other visits as indicated in Appendix A. For 
inpatients, a brief physical examination, targeted to patient symptoms, will be performed at the 
other visits. For outpatients, telemedicine-based physical examinations will be performed at the 
other visits (if the patient and site have video capabilities). Telemedicine-based physical 
examinations may include assessments of general condition (eg, overall appearance and patient 
orientation) and an assessment of the work of breathing (eg, speech cadence, lifting hands above 
head). If the patient or the site do not have video capabilities, the video portion of the 
telemedicine-based physical examination will be omitted, and the visit will be performed by phone. 
In this case and in lieu of the physical or video examination, clinicians will document whether the 
patient is having audible shortness of breath or difficulty speaking. If there are any concerns, then 
the patient will be instructed to call to his/her local physician or be seen at his/her local emergency 
department.  

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 52 of 74 
Version 3.0, 12 May 2021 
9 
STATISTICS 
9.1 
Analysis Populations 
The following analysis populations are defined for this study: 
Intent-to-Treat (ITT) Population: The ITT Population is defined as all randomized patients. The 
ITT Population will be the primary population for analysis of efficacy data. Efficacy analyses will 
be based on the assigned treatment group. 
Safety Population: The Safety Population is defined as all randomized patients who receive at least 
1 dose of study drug. All safety data will be analyzed using the Safety Population. Safety analyses 
will be based on the treatment actually received. 
Per-Protocol (PP) Population: The PP Population is defined as all patients in the ITT Population 
who complete the study with no major protocol deviations that may impact the primary efficacy 
assessment. The primary analysis will be repeated on the PP Population. Major protocol deviations 
will include violations of key entry criteria or deviations that could significantly impact the 
assessment or interpretation of efficacy data. 
PK Population: The PK Population is defined as all patients with at least 1 PK measurement drawn 
during the study. 
9.2 
Statistical Methods 
9.2.1 
Analysis of Efficacy 
Patients who discontinue the study drug will remain in the study to have safety and efficacy 
assessments performed. Patients should be encouraged to follow-up for key study visits (Day 28 
and Day 60) but will not be required to attend every study visit. The data observed on-study will 
be used for analysis regardless of any intercurrent events. Patients who die or discontinue treatment 
prior to the assessment time point (Day 28 or Day 60) because of lack of efficacy, and cannot have 
clinical status determined at the time point, will be considered treatment failures. Details regarding 
data handling and imputation method will be provided in the Statistical Analysis Plan (SAP). 
9.2.1.1 
Primary efficacy analysis 
The primary efficacy endpoint is the proportion of patients alive and not requiring non-invasive or 
invasive ventilation (ie, not receiving high-flow nasal cannula, non-invasive positive pressure 
ventilation, invasive mechanical ventilation, or ECMO) at Day 28. The treatment group difference 
of the response proportions, along with the corresponding 95% confidence interval and p-value, 
will be provided using the logistic regression model by Guo et al. (2012)24 and Ge et al. (2011),25 
adjusted for stratification factor (use of invasive mechanical ventilation at the time of 
randomization [yes or no]). Additional prognostic baseline covariates (eg, age, region, body mass 
index) may be added as covariates/factors into the model to increase precision in the estimation of 
difference in proportions. Details will be provided in the SAP. 
The primary analysis will be repeated on the PP Population. 
9.2.1.2 
Secondary efficacy analysis 
The key secondary endpoints of the proportion of patients alive and not requiring non-invasive or 
invasive ventilation (ie, not receiving high-flow nasal cannula, non-invasive positive pressure 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 53 of 74 
Version 3.0, 12 May 2021 
ventilation, invasive mechanical ventilation, or ECMO) at Day 60, the proportion of patients on 
invasive mechanical ventilation at Day 28 and at Day 60, and the proportion of patients alive at 
Day 28 and Day 60, will be analyzed using the same method as for the primary analysis. 
Tipping point method will be used as a sensitivity analysis for evaluating the robustness of the 
results for the primary endpoint and key secondary endpoints. 
Other secondary endpoints will be analyzed as described in the SAP. For all endpoints defined by 
events, the time points are defined as the number of days after randomization. 
The Phase 2 study is not powered. No alpha controlling strategy will be implemented.  
9.2.1.3 
Multiplicity in Phase 3 
To control the overall Type I error in the final analysis for Phase 3, a fixed sequential testing 
procedure will be implemented. In a hierarchical step-down manner, the primary efficacy endpoint 
will be tested at the 1-sided 0.025 level first, followed by testing the secondary efficacy endpoints 
at the 1-sided 0.025 level in the following hierarchical manner: (1) proportion of patients on 
invasive mechanical ventilation at Day 28, (2) proportion of patients alive at Day 28, (3) proportion 
of patients alive and not requiring non-invasive or invasive ventilation (ie, not receiving high-flow 
nasal cannula, non-invasive positive pressure ventilation, invasive mechanical ventilation, or 
ECMO) at Day 60, (4) proportion of patients on invasive mechanical ventilation at Day 60, and 
(5) proportion of patients alive at Day 60.  
Inferential conclusions about these efficacy endpoints will require statistical significance of the 
previous endpoints and the primary efficacy endpoint. 
This is not applicable to Phase 2 since Phase 2 is not powered.  
9.2.1.4 
Pharmacokinetic analysis 
PK data will be summarized.  
9.2.2 
Analysis of Safety 
Safety data will be summarized by actual treatment received, and in total for selected 
analyses/summaries, based on the Safety Population, and include the following: 
• AEs and SAEs; 
• Clinical laboratory assessments (including clinical chemistry, hematology, and urinalysis); 
• Vital signs; 
• Physical examinations; and 
• 12-lead ECGs. 
9.2.3 
Analysis Timing 
Primary analysis (Phase 2) 
A primary analysis will be conducted once all patients in Phase 2 complete the EOT Visit on 
Day 28 or have discontinued early but would have reached Day 28 had they remained in the study. 
The results will be conducted by an independent statistician and reviewed by the iDMC following 
the procedures defined in the iDMC Charter. The iDMC will convene to recommend dose selection 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 54 of 74 
Version 3.0, 12 May 2021 
and whether to adjust study design for Phase 3 based on this analysis. The study team will remain 
blinded. Designated personnel from the Sponsor will have access to the analysis results. The 
Phase 3 sample size and interim analysis boundaries will be recalculated based on the Phase 2 
primary analysis results. 
Final analysis (Phase 2 and Phase 3) 
For each phase (Phase 2 and Phase 3), after all the patients have completed (discontinued) the 
study and the database is locked, the data will be unblinded and the final analysis will be performed.  
Interim analysis 
No interim analysis is planned for Phase 2. 
For Phase 3, an interim analysis will be performed once approximately 70% of the randomized 
patients complete the EOT Visit on Day 28 or have discontinued early but would have reached 
Day 28 had they remained in the study. The iDMC will convene to evaluate for safety, early futility, 
and potential sample size recalculation. 
For the futility interim analyses, the iDMC will be guided by a pre-specified non-binding futility 
monitoring boundary based on the gamma family spending function (with parameter ϒ = -4, 
calculated using EAST 6.4, see Table 1). Non-binding for the futility indicates that the futility 
boundary is constructed in such a way that it can be overruled by the iDMC without inflating the 
type I error and without decreasing power. The iDMC will also consider all available efficacy and 
safety data prior to formulating its recommendations regarding continuation or termination of the 
study due to early futility.  
Although the study does not intend to stop early for outstanding efficacy in the interim analysis, a 
small alpha (0.0001) will be spent in order to protect data integrity and to preserve an overall 
1-sided significant level of 0.025 for the primary analysis. 
Table 1. Futility Boundaries in the Interim and Final Analyses of Overall Success Rate 
Based on a 1-Sided Test at the 0.025 Level 
Planned 
Analysis  
Total 
Completers 
[1] 
Information 
Fraction  
Futility Boundary 
Boundary Crossing 
Probability 
(Incremental) 
Cumulative 
Beta Spent 
Z Scale 
Nominal 
P-Value 
Under H0 
Under H1 
Interim 
213 
0.7 
0.789 
0.2151 
0.785 
0.057 
0.0572 
Final 
304 
1 
1.960 
0.025 
0.191 
0.141 
0.198 
1. 
Patients who complete the Day 28 visit or discontinue early, but would have reached Day 28. 
Futility testing (Phase 3) 
The process is as follows:  
• Futility at the interim analysis: If the 1-sided p-value is ≥0.2151 (or the observed z-statistic is 
≤0.789), then the futility boundary is crossed and the null hypothesis will be accepted; and 
• At the final analysis: The final hypothesis is tested at the 1-sided significance level of 0.025.  
In case the number of patients at the interim analyses are not exactly equal to the planned number 
of patients (ie, the first 213 patients who completed the EOT Visit on Day 28 or have discontinued 
early but would have reached Day 28), the futility boundary will be revised based on the actual 
number of patients at the interim analysis. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 55 of 74 
Version 3.0, 12 May 2021 
Sample size recalculation (Phase 3) 
At the interim analysis for early futility, when the first 213 patients complete the EOT Visit on 
Day 28 or have discontinued early but would have reached Day 28, the iDMC will also assess for 
potential sample size recalculation for the study using the promising-zone method. Wald 
conditional probabilities will be calculated using the actual observed proportions from both 
treatment arms. The maximum sample size allowed is 608 patients. Sample size will be increased 
only if the observed data at the interim analysis are promising; that is, if the conditional power 
is ≥36% and <80%, as described in the SAP. 
Possible recommendations by the iDMC 
After reviewing the results of the interim analysis, the iDMC may select 1 of 4 or more possible 
recommendations, based on the test statistics obtained at the interim analysis, as follows: 
• Stop for early futility: Stop study early due to strong evidence for futility due to test statistic 
being in the futility region;  
• Continue without change: Continue with no changes due to test statistic not being in the futility 
region or the conditional power being <36% or ≥80%; 
• Add required additional sample size, n, without exceeding the maximum sample size and 
continue the study; or 
• Stop for safety concerns. 
9.2.4 
Independent Data Monitoring Committee 
An iDMC with multidisciplinary representation and pertinent expertise will be established to 
evaluate accumulating study data and to oversee the ongoing safety of the study for the patients 
enrolled. The iDMC will be external to the Sponsor. The iDMC will meet at 4 scheduled times, as 
described below, and more frequently if needed, to provide safety oversight for patients (see 
Section 4.3). Only the iDMC members and an independent statistician will have access to 
unblinded comparative results. The study team will remain blinded, except as noted above for the 
Phase 2 primary analysis. 
The iDMC will convene during the Phase 2 study at 2 pre-planned time points, once after 
approximately 10 to 15 patients have been enrolled and a second time after approximately 50% to 
60% of patients have been enrolled. For each pre-planned meeting, the decision to have an 
associated pause in enrollment will be made by the chairperson of the iDMC (with input from the 
Medical Monitor). The decision will be based on the type of safety data to be provided for review 
and taking into account whether continuing enrollment could place study patients at risk. Based 
on safety and efficacy evaluations using unblinded data, the iDMC may make recommendation(s) 
to the Sponsor to continue the study with or without modifications or, for safety reasons, terminate 
the study. The Sponsor will make the final decision to terminate the study. No formal statistical 
testing will be conducted. 
In addition, a primary analysis will be conducted once all patients in the Phase 2 study complete 
the EOT Visit on Day 28. The analysis will be conducted by an independent statistician and 
reviewed by the iDMC. The Sponsor (key personnel only) will also be able to review the data at 
this time. The iDMC will convene to recommend dose selection and whether to adjust study design 
(eg, eligibility criteria, sample size number, protocol-defined procedures, and timing of procedures) 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 56 of 74 
Version 3.0, 12 May 2021 
for Phase 3 based on this analysis. If the iDMC recommends modification of the protocol, and the 
Sponsor is in agreement, the protocol will be amended. Enrollment of any patients for Phase 3 will 
not begin until after completion of the assessment of the primary analysis. 
During the Phase 3 study, an interim analysis will be performed once approximately 70% of the 
randomized patients (approximately 213 patients) complete the EOT Visit on Day 28 or have 
discontinued early but would have reached Day 28 had they remained in the study. Enrollment of 
new patients will be paused during the interim analysis. The iDMC will convene, evaluating for 
safety, early futility, and potential sample size recalculation. The interim analysis of the primary 
endpoint will be for early futility only. The study will not be stopped for overwhelming efficacy.  
Based on ongoing safety monitoring of the study, additional ad hoc iDMC reviews may be 
conducted. For these ad hoc meetings, the decision to have an associated pause in enrollment will 
be made by the chairperson of the iDMC (with input from the Medical Monitor). Further details 
regarding the role, responsibilities, and procedures of the iDMC will be provided in the iDMC 
Charter.  
In addition, manual reviews of safety data will be performed throughout the study by appropriate 
study personnel and the Medical Monitor. Study personnel and the Medical Monitor will be 
blinded to the patient treatment assignments throughout the study; however, in the event of an 
emergency or AE for which it is necessary to know the study drug to determine an appropriate 
course of therapy for the patient, unblinding may occur (see Section 5.4). 
9.2.5 
Sample Size Determination 
For the Phase 2 study, approximately 99 patients will be randomized in a 1:1:1 ratio to 1 of 
3 treatment groups: FP-025 100 mg BID, FP-025 300 mg BID, or placebo BID. No formal 
statistical assessment for sample size determination has been performed. The sample size is 
considered adequate to provide the necessary data to evaluate the objectives of the study. 
For Phase 3, a total of 304 patients (152 patients per treatment group) will provide approximately 
80% power to detect a 15% improvement in response rate, based on a control response rate of 60% 
and assuming a response rate of 75% with the study drug treatment group, using a 1-sided 
0.025 level test. The sample size estimate assumes that an interim analysis will be conducted after 
approximately 70% of patients (approximately 213 patients) have completed the EOT Visit on 
Day 28 or have discontinued early, but would have reached Day 28 had they remained in the study, 
to assess early futility and potential sample size recalculation. The sample size was calculated 
using EAST 6.4. The Phase 3 sample size will be formally recalculated based on results from the 
Phase 2 part of the study. A maximum of 608 patients may be included. If the iDMC, in 
consultation with the Sponsor determines that a sample size of more than 608 patients is needed, 
a protocol amendment will be required. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 57 of 74 
Version 3.0, 12 May 2021 
10 
DATA MANAGEMENT AND RECORD KEEPING 
10.1 
Data Management 
10.1.1 
Data Handling 
Data will be recorded at the center on eCRFs and reviewed by the CRA during monitoring visits 
or during remote monitoring. The CRAs will verify data recorded in the EDC system with source 
documents. All corrections or changes made to any study data must be appropriately tracked in an 
audit trail in the EDC system. An eCRF will be considered complete when all missing, incorrect, 
and/or inconsistent data has been accounted for. 
10.1.2 
Computer Systems 
Data will be processed using a validated computer system conforming to regulatory requirements. 
10.1.3 
Data Entry 
Data must be recorded using the EDC system as the study is in progress. All center personnel must 
log into the system using their secure user name and password in order to enter, review, or correct 
study data. These procedures must comply with Title 21 of the Code of Federal Regulations (CFR) 
(21 CFR Part 11) and other appropriate international regulations. All passwords will be strictly 
confidential. 
10.1.4 
Medical Information Coding 
For medical information, the following thesauri will be used: 
• Medical Dictionary for Regulatory Activities (latest) for medical history and AEs; and 
• World Health Organization Drug Dictionary (latest) for prior and concomitant medications. 
10.1.5 
Data Validation 
Validation checks programmed within the EDC system, as well as supplemental validation 
performed via review of the downloaded data, will be applied to the data in order to ensure accurate, 
consistent, and reliable data. Data identified as erroneous, or data that are missing, will be referred 
to the center for resolution through data queries. 
The eCRFs must be reviewed and electronically signed by the Investigator. 
10.2 
Record Keeping 
Records of patients, source documents, monitoring visit logs, eCRFs, inventory of study product, 
regulatory documents, and other Sponsor correspondence pertaining to the study must be kept in 
the appropriate study files at the center. Source data is defined as all information in original records 
and certified copies of original records of clinical findings, observations, or other activities in a 
study necessary for the evaluation and reconstruction of the study. Source data are contained in 
source documents (original records or certified copies). These records will be retained in a secure 
file for the period as set forth in the Clinical Study Agreement. Prior to transfer or destruction of 
these records, the Sponsor must be notified in writing and be given the opportunity to further store 
such records.  

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 58 of 74 
Version 3.0, 12 May 2021 
10.3 
End of Study 
The end of the study (“study completion”) is defined as the date of the last protocol-specified 
visit/assessment (including telephone contact) for the last patient in the study. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 59 of 74 
Version 3.0, 12 May 2021 
11 
INVESTIGATOR REQUIREMENTS AND QUALITY CONTROL  
11.1 
Ethical Conduct of the Study 
Good Clinical Practice (GCP) is an international ethical and scientific quality standard for 
designing, conducting, recording, and reporting studies that involve human patients. Compliance 
with this standard provides public assurance that the rights, safety, and wellbeing of study patients 
are protected, consistent with the principles that have their origin in the Declaration of Helsinki, 
and that the study data are credible. 
11.2 
Institutional Review Board 
The IRB will review all appropriate study documentation in order to safeguard the rights, safety, 
and well-being of patients. The study will only be conducted at centers where IRB approval has 
been obtained. The protocol, Investigator’s Brochure, informed consent form (ICF), 
advertisements (if applicable), written information given to the patients, safety updates, annual 
progress reports, and any revisions to these documents will be provided to the IRB by the 
Investigator. 
Federal regulations and International Council for Harmonisation (ICH) Guidelines require that 
approval be obtained from an IRB prior to participation of patients in research studies. Prior to 
study onset, the protocol, any protocol amendments, ICFs, advertisements to be used for patient 
recruitment, and any other written information regarding this study to be provided to a patient or 
patient’s legal guardian must be approved by the IRB. 
No drug will be released to the center for dosing until written IRB authorization has been received 
by the Sponsor. 
11.3 
Informed Consent 
The ICF and any changes to the ICF made during the course of the study must be agreed to by the 
Sponsor or designee and the IRB prior to its use and must be in compliance with all ICH GCP, 
local regulatory requirements, and legal requirements.  
The Investigator must ensure that each study patient is fully informed about the nature and 
objectives of the study and possible risks associated with participation and must ensure that the 
patient has been informed of his/her rights to privacy. The Investigator will obtain written informed 
consent from each patient before any study-specific activity is performed and should document in 
the source documentation that consent was obtained prior to enrollment in the study. The original 
signed copy of the ICF must be maintained by the Investigator and is subject to inspection by a 
representative of the Sponsor, their representatives, auditors, the IRB, and/or regulatory agencies. 
A copy of the signed ICF will be given to the patient. 
11.4 
Study Monitoring Requirements 
It is the responsibility of the Investigator to ensure that the study is conducted in accordance with 
the protocol, Declaration of Helsinki, ICH GCP, and applicable regulatory requirements, and that 
valid data are entered into the eCRFs. 
To achieve this objective, the CRA’s duties are to aid the Investigator and, at the same time, the 
Sponsor in the maintenance of complete, legible, well organized and easily retrievable data. Before 
the enrollment of any patient in this study, the Sponsor or their designee will review with the 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 60 of 74 
Version 3.0, 12 May 2021 
Investigator and center personnel the following documents: protocol, Investigator’s Brochure, 
eCRFs and procedures for their completion, informed consent process, and the procedure for 
reporting SAEs. 
The Investigator will permit the Sponsor or their designee to monitor the study as frequently as 
deemed necessary to determine that data recording and protocol adherence are satisfactory. During 
the monitoring visits, information recorded on the eCRFs will be verified against source 
documents and requests for clarification or correction may be made. After the eCRF data is entered 
by the center, the CRA will review the data for safety information, completeness, accuracy, and 
logical consistency. Computer programs that identify data inconsistencies may be used to help 
monitor the study. If necessary, requests for clarification or correction will be sent to Investigators. 
The Investigator and his/her staff will be expected to cooperate with the CRA and provide any 
missing information, whenever possible. 
All monitoring activities will be reported and archived. In addition, monitoring visits will be 
documented at the center by signature and date on the study-specific monitoring log. 
11.5 
Disclosure of Data 
Data generated by this study must be available for inspection by the FDA, the Sponsor or their 
designee, applicable foreign health authorities, and the IRB as appropriate. Patients or their legal 
representatives may request their medical information be given to their personal physician or other 
appropriate medical personnel responsible for their welfare. 
Patient medical information obtained during the study is confidential and disclosure to third parties 
other than those noted above is prohibited. 
11.6 
Retention of Records 
To enable evaluations and/or audits from regulatory authorities or the Sponsor, the Investigator 
will keep records, including the identity of all participating patients (sufficient information to link 
records, eg, eCRFs and hospital records), all original signed ICFs, copies of all eCRFs, SAE forms, 
source documents, and detailed records of treatment disposition. The records should be retained 
by the Investigator according to specifications in the ICH guidelines, local regulations, or as 
specified in the Clinical Study Agreement, whichever is longer. The Investigator must obtain 
written permission from the Sponsor before disposing of any records, even if retention 
requirements have been met. 
If the Investigator relocates, retires, or for any reason withdraws from the study, the Sponsor should 
be prospectively notified. The study records must be transferred to an acceptable designee, such 
as another Investigator, another institution, or to the Sponsor.  
11.7 
Publication Policy 
Following completion of the study, the data may be considered for publication in a scientific 
journal or for reporting at a scientific meeting. Each Investigator is obligated to keep data 
pertaining to the study confidential. The Investigator must consult with the Sponsor before any 
study data are submitted for publication. The Sponsor reserves the right to deny publication rights 
until mutual agreement on the content, format, interpretation of data in the manuscript, and journal 
selected for publication are achieved. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 61 of 74 
Version 3.0, 12 May 2021 
11.8 
Financial Disclosure 
Investigators are required to provide financial disclosure information to the Sponsor to permit the 
Sponsor to fulfill its obligations under 21 CFR Part 54. In addition, Investigators must commit to 
promptly updating this information if any relevant changes occur during the study and for a period 
of 1 year after the completion of the study. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 62 of 74 
Version 3.0, 12 May 2021 
12 
STUDY ADMINISTRATIVE INFORMATION 
12.1 
Protocol Amendments 
Any amendments to the study protocol will be communicated to the Investigators by Medpace or 
the Sponsor. All protocol amendments will undergo the same review and approval process as the 
original protocol. A protocol amendment may be implemented after it has been approved by the 
IRB, unless immediate implementation of the change is necessary for patient safety. In this case, 
the situation must be documented and reported to the IRB within 5 working days. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 63 of 74 
Version 3.0, 12 May 2021 
13 
REFERENCES 
 
1. 
Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 
2019;17(3):181-192.   
2. 
Petrosillo N, Viceconte G, Ergonul O, et al. COVID-19, SARS, and MERS: are they 
closely related? Clin Microbiol Infect. 2020;26(6):729-734. 
3. 
Tan W, Zhao X, Ma X, et al. Notes from the field: a novel coronavirus genome identified 
in a cluster of pneumonia cases − Wuhan, China 2019−2020. China CDC Weekly. 
2020;2(4):61-62. 
4. 
Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19): cases 
in the U.S. https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html. 
Accessed 13 October 2020. 
5. 
Oran DP, Topol EJ. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative 
review [published online ahead of print, 2020 June 3]. Ann Intern Med. 2020;M20-3012. 
doi:10.7326/M20-3012. 
6. 
Zaim S, Chong JH, Sankaranarayanan V, et al. COVID-19 and multiorgan response. 
Curr Probl Cardiol. 2020;45(8):100618. 
7. 
Centers for Disease Control and Prevention. Interim clinical guidance for management of 
patients with confirmed coronavirus disease (COVID-19). Updated 30 June 2020. 
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-
patients.html. Accessed 14 July 2020. 
8. 
Walkey AJ, Summer R, Ho V, et al. Acute respiratory distress syndrome: epidemiology 
and management approaches. Clin Epidemiol. 2012;4(1):159-169. 
9. 
Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the 
Seattle region – case series. N Engl J Med. Published online 30 March 2020. 
doi:10.1056/NEJMoa2004500. 
10. 
Arentz M, Yim E, Klaff L. Characteristics and outcomes of 21 critically ill patients with 
COVID-19 
in 
Washington 
State. 
JAMA. 
2020;323(16):1612-1614. 
doi:10.1001/jama.2020.4326. 
11. 
Masclans JR, Roca O, Muñoz X, et al. Quality of life, pulmonary function, and 
tomographic scan abnormalities after ARDS. Chest. 2011;139(6):1340-1346. 
12. 
Zhang P, Li J, Liu H, et al. Long-term bone and lung consequences associated with 
hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a 
prospective cohort study. Bone Res. 2020; 8:8. 
13. 
Das KM, Lee EY, Singh R, et al. Follow-up chest radiographic findings in patients with 
MERS-CoV after recovery. Indian J Radiol Imaging. 2017;27(3):342‐349. 
14. 
Thille AW, Esteban A, Fernández-Segoviano P, et al. Chronology of histological lesions 
in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort 
study of clinical autopsies. Lancet Respir Med. 2013;1(5):395-401. 
15. 
George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role 
for antifibrotic therapy [published online ahead of print, 2020 May 15]. Lancet Respir Med. 
2020;S2213-2600(20)30225-3. doi:10.1016/S2213-2600(20)30225-3. 
16. 
Gimenes JA Jr, Srivastava V, ReddyVari H, et al. Rhinovirus-induces progression of lung 
disease in a mouse model of COPD via IL-33/ST2 signaling axis. Clin Sci (Lond). 
2019;133(8):983-996. 
 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 64 of 74 
Version 3.0, 12 May 2021 
 
17. 
Chiba Y, Yu Y, Sakai H, et al. Increase in the expression of matrix metalloproteinase-12 
in the airways of rats with allergic bronchial asthma. Biol Pharm Bull. 2007;30(2):318-323. 
18. 
Churg A, Wang R, Wang X, et al. Effect of an MMP-9/MMP-12 inhibitor on 
smoke-induced 
emphysema 
and 
airway 
remodelling 
in 
guinea 
pigs. Thorax. 
2007;62(8):706-713. 
19. 
Molet S, Belleguic C, Lena H, et al. Increase in macrophage elastase (MMP-12) in lungs 
from patients with chronic obstructive pulmonary disease. Inflamm Res. 2005;54(1):31-36. 
20. 
Huizar I, Malur A, Midgette YA, et al. Novel murine model of chronic granulomatous lung 
inflammation elicited by carbon nanotubes. Am J Respir Cell Mol Biol. 
2011;45(4):858-866. 
21. 
Mohan A, Malur A, McPeek M, et al. Transcriptional survey of alveolar macrophages in a 
murine model of chronic granulomatous inflammation reveals common themes with 
human sarcoidosis. Am J Physiol Lung Cell Mol Physiol. 2018;314(4):L617-L625. 
22. 
Crouser ED, Culver DA, Knox KS, et al. Gene expression profiling identifies MMP-12 and 
ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir 
Crit Care Med. 2009;179(10):929-938. 
23. 
Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis: an 
official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 
2018;198(5):e44-e68. 
24. 
Guo Y, Wu V, Li X, et al. Covance Pharmaceutical Research and Development (Beijing) 
Co., Ltd. An illustration of rate difference estimation with SAS in logistic regression. 
PharmaSUG China 1st Conference. 2012. https://www.lexjansen.com/pharmasug-
cn/2012/papers/PharmaSUG_China_2012_d3.pdf. Accessed 14 December 2020. 
25. 
Ge M, Durham LK, Meyer RD, et al. Covariate-adjusted difference in proportions from 
clinical trials using logistic regression and weighted risk differences. Ther Innov Regul Sci. 
2011;45(4):481-493. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
 
 
    Page 65 of 74 
Version 3.0, 12 May 2021 
APPENDIX A: SCHEDULE OF PROCEDURES 
Table 2. Schedule of Procedures: Inpatient Admission Through Day 28 
 
Screening 
Visit 
Treatment Period 
Follow-Up Period 
ET Visitb 
Visit 
1 
2 
3 
4 
5 
6 
7/EOT 
8 
9 
Study Day 
-1 to 1 
1 
4 
7 
14 
21 
28 
45a 
60 
Visit Window 
(Days) 
− 
±3 
±3 
±3 
±3 
±3 
±3 
±7 
±7 
Unscheduled 
Informed consentc 
X 
 
 
 
 
 
 
 
 
 
I/E criteria 
X 
Xd 
 
 
 
 
 
 
 
 
Demographic 
information 
X 
 
 
 
 
 
 
 
 
 
Medical/surgical 
history 
X 
Xd 
 
 
 
 
 
 
 
 
Assessment of 
standard of caree 
 
X-----------------------------------------------------------X 
 
 
 
Prior/concomitant 
medications 
X 
X----------------------------------------------------------X 
X 
X 
X 
Weight and heightf 
X 
X 
 
 
 
 
X 
 
X 
X 
Physical 
examinationg 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
Vital signs including 
SpO2h 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
PaO2/FiO2 ratioi 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
hCGj 
X 
 
 
 
 
 
X 
 
X 
X 
Viral respiratory 
panelk 
X 
 
 
 
 
 
 
 
 
 
12-lead ECGl 
 
X 
X 
X 
X 
X 
X 
 
 
X 
SARS-CoV-2 PCRm 
X 
 
 
 
 
 
 
 
 
 
Clinical laboratory 
assessmentsn 
X 
X 
X 
X 
X 
X 
X 
 
X 
X 
PK blood samplingo 
 
X 
X 
X 
X 
X 
X 
 
 
 
Randomization 
 
X 
 
 
 
 
 
 
 
 
Footnotes at the end of table. 
 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
 
 
    Page 66 of 74 
Version 3.0, 12 May 2021 
Table 2. Schedule of Procedures: Inpatient Admission Through Day 28 (Continued) 
 
Screening 
Visit 
Treatment Period 
Follow-Up Period 
ET Visitb 
Visit 
1 
2 
3 
4 
5 
6 
7/EOT 
8 
9 
 
Study Day 
-1 to 1 
1 
4 
7 
14 
21 
28 
45a 
60 
Visit Window 
(Days) 
− 
±3 
±3 
±3 
±3 
±3 
±3 
±7 
±7 
Unscheduled 
Study drug 
administrationp 
 
X 
X 
X 
X 
X 
X 
 
 
 
High resolution, 
non-contrast CT scan 
of the chestq 
X 
 
 
 
 
 
X 
 
X 
X 
PFTsr 
 
 
 
 
 
 
 
 
X 
X 
Biomarker 
assessment (blood)s 
 
X 
 
X 
X 
 
X 
 
X 
X 
NIAID 8-point 
ordinal scale 
assessment 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
AEs/SAEst 
 
X-----------------------------------------------------------------------------------------------------------X 
X 
Note: If the study drug is discontinued but the patient is remaining in the study, the patient should be encouraged to remain in the study and to follow-up for key study visits (Day 28 
and Day 60) but will not be required to attend every study visit. If the patient withdraws, he/she should complete the ET Visit. 
a. 
The Day 45 visit will be a telephone visit only. 
b. 
If a patient withdraws prematurely from the study, study staff should make every effort to complete the full panel of assessments scheduled for the ET visit. The reason for 
patient withdrawal must be documented in the eCRF. 
c. 
The Investigator will obtain written informed consent from each patient before any study-specific activity is performed. 
d. 
I/E criteria and medical/surgical history will be reviewed again on Day 1 (Visit 2) prior to randomization. Any updates since the Screening Visit will be assessed.  
e. 
The standard of care followed for each patient and center and whether any care decisions were based on resource limitations will be clearly documented for all patients. 
f. 
Height will be collected at the Screening Visit only and will be used to calculate body mass index. Height and weight may also be obtained from the most recent medical record 
if the site is unable to obtain these values. 
g. 
A full physical examination will be performed at the Screening Visit, the EOT Visit, and Day 60. A full physical examination may include assessments of general condition, 
skin, eyes/ears/nose/mouth/throat, neck/thyroid, chest/lungs, heart, vascular system, lymph nodes, abdomen, extremities, nervous systems/reflexes, musculoskeletal system, and 
spine. A brief physical examination, targeted to patient symptoms, will be performed at the other visits. 
h. 
Vital signs include temperature, heart rate, respiratory rate, blood pressure, and SpO2. 
i. 
A PaO2, obtained via arterial blood gas will be used to calculate the PaO2/FiO2 ratio, only in patients on invasive or non-invasive ventilation. 
j. 
For WCBP only. Serum hCG will be performed at the Screening Visit. If performed within 24 hours before the Screening Visit, a historical serum hCG test can be used. Urine 
hCG will be performed at all other visits.  
k. 
See Appendix B for a list of viruses that will be tested. 
l. 
ECGs should be performed 2 hours (±30 minutes) after the first study drug administration on Day 1 and 2 hours (±30 minutes) after the morning dose on Day 4 and Day 7. 
ECGs may be performed at any time at subsequent visits. Patients should be in a supine position for at least 10 minutes prior to ECG measurement. 
m. SARS-CoV-2 testing may be performed at the Screening Visit. The patient must have a documented, laboratory-confirmed SARS-CoV-2 infection as determined by reverse 
transcriptase PCR (or an equivalent test) immediately prior to or during the current hospitalization to be included in the study. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
 
 
    Page 67 of 74 
Version 3.0, 12 May 2021 
n. 
Clinical laboratory assessments include clinical chemistry, hematology, and urinalysis. See Appendix B for a list of clinical laboratory analytes.  
o. 
PK sampling times will be as follows: Day 1 (Visit 2) pre-dose and at 1 hour (±10 minutes), 3 hours (±10 minutes), and 8 hours (±10 minutes) post the first morning dose of 
study drug (if the patient is randomized in the afternoon on Day 1 [Visit 2], this will be performed after the morning dose of study drug on Day 2); Day 4, Day 7, Day 14, and 
Day 21 within 1 hour (±10 minutes) prior to the morning dose; and Day 28 within 1 hour (±10 minutes) prior to the morning dose and 1 hour (±10 minutes) post-morning dose.  
p. 
The study drug (FP-025 100 mg, FP-025 300 mg, or placebo) will be administered orally as capsules or via a polyvinyl chloride nasogastric tube (by opening up the capsules 
and delivering as a suspension in orange juice) BID for 28 days. Capsules can also be opened and added to orange juice to drink. 
q. 
A chest radiograph may be substituted for the high-resolution, non-contrast CT scan at the Screening Visit only for study eligibility. High-resolution, non-contrast CT scans 
should be performed at subsequent visits (Day 28 and Day 60) to assess for lung fibrosis.  
r. 
PFTs will include measurement of FVC, FEV1, FEV1/FVC ratio, and diffusing capacity of the lungs for carbon monoxide. 
s. 
Inflammatory and fibrotic biomarkers assessed may include, but are not limited to, MMP-12, MMP-7, MMP-9, TGF-β, connective tissue growth factor, PRO-C3, PRO-C4, 
PRO-C6, reC1M, C4M, C6M, CRPM, X-FIB (D-dimer), C-reactive protein, cytokines (IFN-γ, TNF-α, IL-6, IL-1β, and C-C motif chemokine ligand 2 [monocyte 
chemoattractant protein-1]), and ferritin levels in blood.  
t. 
AEs will be monitored and recorded from the time of the first dose of study drug (Day 1 [Visit 2]) until the end of the study (Day 60). Any SAE that is ongoing at the end of 
the study (Day 60) will be followed by the Investigator until the SAE has subsided or until the condition(s) becomes chronic in nature, until the patient begins alternative 
treatment for COVID-19, until the condition(s) stabilizes (in the case of persistent impairment), or until the patient dies. 
AE = adverse event; BAL = bronchoalveolar lavage; BID = twice daily; C4M = neo-epitope of MMP-2, 9-, and 12-mediated degradation of type IV collagen; C6M = neo-epitope of 
MMP-2-mediated degradation of type VI collagen; CoV = coronavirus; CRPM = neo-epitope of MMP-1 and 8-mediated degradation of C-reactive protein; CT = computed 
tomography; ECG = electrocardiogram; eCRF = electronic case report form; EOT = End of Treatment; ET = Early Termination; FEV1 = forced expiratory volume in 1 second; 
FiO2 = fractional inspired oxygen; FVC = forced vital capacity; hCG = human chorionic gonadotropin; I/E = inclusion and exclusion; ICF = informed consent form; IFN = interferon; 
IL = interleukin; MMP = matrix metalloproteinase; NIAID = National Institute of Allergy and Infectious Diseases; PaO2 = arterial oxygen partial pressure; PCR = polymerase chain 
reaction; PFT = pulmonary function test; PK = pharmacokinetic(s); PRO-C3 = released N-terminal pro-peptide of type III collagen; PRO-C4 = internal epitope in the 7S domain of 
type IV collagen; PRO-C6 = C-terminal of released C5 domain of type VI collagen α3 chain (endotrophin); reC1M = neo-epitope of MMP-2, 9-, and 13-mediated degradation of 
type I collagen; SARS = severe acute respiratory syndrome; SpO2 = peripheral capillary oxygen saturation; TGF = transforming growth factor; TNF = tumor necrosis factor; 
WCBP = woman/women of childbearing potential; X-FIB (D-dimer) = neo-epitope of plasmin-mediated degradation of cross-linked fibrin. 
 
 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
 
 
    Page 68 of 74 
Version 3.0, 12 May 2021 
Table 3. Modified Schedule of Procedures for Discharged Patients 
 
Treatment Period 
Follow-Up Period 
 
Visit 
Day of 
Dischargea 
O1b 
O2b 
O3b 
11/EOT 
12 
13 
 
Study Day 
Xc 
X + 7d 
X + 14d 
X + 21d 
28 
45e 
60 
ET Visitf 
Visit Window (Days) 
±2 
±3 
±3 
±3 
±3 
±7 
±7 
Unscheduled 
Assessment of standard of 
care treatmentg 
X---------------------------------------------------------------------------------------X 
 
 
 
Prior/concomitant 
medications 
X---------------------------------------------------------------------------------------X 
X 
X 
X 
Weight 
X 
 
 
 
X 
 
X 
X 
Physical examinationh 
X 
X 
X 
X 
X 
 
X 
X 
Vital signs including SpO2i 
X 
X 
X 
X 
X 
 
X 
X 
Urine hCGj 
 
 
 
 
X 
 
X 
X 
12-lead ECGk 
X 
 
 
 
X 
 
 
X 
Clinical laboratory 
assessmentsl 
X 
 
 
 
X 
 
X 
X 
PK blood samplingm 
 
 
 
 
X 
 
 
 
Study drug provided for 
rest of study period 
X 
 
 
 
 
 
 
 
Study drug 
self-administrationn 
 
X 
X 
X 
X 
 
 
 
High resolution, 
non-contrast CT scan of the 
chest 
 
 
 
 
X 
 
X 
X 
PFTso 
 
 
 
 
 
 
X 
X 
Biomarker assessment 
(blood)p 
X 
 
 
 
X 
 
X 
X 
NIAID 8-point ordinal 
scale assessment 
X 
 
 
 
X 
X 
X 
X 
AEs/SAEsq 
X 
X------------------------------------------------------------------------------------------------------X 
X 
Note: If the study drug is discontinued but the patient is remaining in the study, the patient should be encouraged to remain in the study and to follow-up for key study visits (Day 28 
and Day 60) but will not be required to attend every study visit. If the patient withdraws, he/she should complete the ET Visit. 
a. 
Discharge visit procedures do not need to be completed if they were done within 24 hours of the discharge date. 
b. 
Outpatient visits during the treatment period will be telemedicine visits (if the patient and site have video capabilities). If the patient or the site do not have video capabilities, a 
telephone visit will be performed instead. 
c. 
The listed assessments will occur on the day of discharge, regardless of what day this occurs on. 
d. 
The first outpatient visit will be 1 week after discharge. Visits will continue weekly until Day 28. The number of outpatient visits will vary depending on the day of discharge. 
e. 
The Day 45 visit will be a telephone visit only. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
 
 
    Page 69 of 74 
Version 3.0, 12 May 2021 
f. 
If a patient withdraws prematurely from the study, study staff should make every effort to complete the full panel of assessments scheduled for the ET visit. The reason for 
patient withdrawal must be documented in the eCRF.  
g. 
The standard of care followed for each patient and center and whether any care decisions were based on resource limitations will be clearly documented for all patients. 
 
h. 
A full physical examination will be performed at EOT and Day 60. A full physical examination may include assessments of general condition, skin, eyes/ears/nose/mouth/throat, 
neck/thyroid, chest/lungs, heart, vascular system, lymph nodes, abdomen, extremities, nervous systems/reflexes, musculoskeletal system, and spine. Telemedicine-based 
physical examinations will be performed at the other visits. Telemedicine-based physical examinations (if the patient and site have video capabilities) may include assessments 
of general condition (eg, overall appearance and patient orientation) and an assessment of the work of breathing (eg, speech cadence, lifting hands above head). If the patient or 
the site do not have video capabilities, the video portion of the telemedicine-based physical examination will be omitted, and the visit will be performed by phone. In this case 
and in lieu of the physical or video examination, clinicians will document whether the patient is having audible shortness of breath or difficulty speaking. If there are any 
concerns, then the patient will be instructed to call to his/her local physician or be seen at his/her local emergency department.  
i. 
Vital signs include temperature, heart rate, respiratory rate, blood pressure, and SpO2. Pulse oximeters, thermometers, and blood pressure cuffs will be provided for home use.  
j. 
For WCBP only.  
k. 
Patients should be in a supine position for at least 10 minutes prior to ECG measurement. 
l. 
Clinical laboratory assessments include clinical chemistry, hematology, and urinalysis. See Appendix B for a list of clinical laboratory analytes. 
m. PK analysis will occur on Day 28 within 1 hour (±10 minutes) prior to the morning dose and 1 hour (±10 minutes) post-morning dose. 
n. 
The study drug (FP-025 100 mg, FP-025 300 mg, or placebo) will be administered orally as capsules BID for 28 days. 
o. 
PFTs will include measurement of FVC, FEV1, FEV1/FVC ratios, and diffusing capacity of the lungs for carbon monoxide. 
p. 
Inflammatory and fibrotic biomarkers assessed may include, but are not limited to, MMP-12, MMP-7, MMP-9, TGF-β, connective tissue growth factor, PRO-C3, PRO-C4, 
PRO-C6, reC1M, C4M, C6M, CRPM, X-FIB (D-dimer), C-reactive protein, cytokines (IFN-γ, TNF-α, IL-6, IL-1β, and C-C motif chemokine ligand 2 [monocyte 
chemoattractant protein-1]), and ferritin levels in blood. 
  
q. 
AEs will be monitored and recorded from the time of the first dose of study drug (Day 1 [Visit 2]) until the end of the study (Day 60). Any SAE that is ongoing at the end of 
the study (Day 60) will be followed by the Investigator until the SAE has subsided or until the condition(s) becomes chronic in nature, until the patient begins alternative 
treatment for COVID-19, until the condition(s) stabilizes (in the case of persistent impairment), or until the patient dies. 
AE = adverse event; BID = twice daily; C4M = neo-epitope of MMP-2, 9-, and 12-mediated degradation of type IV collagen; C6M = neo-epitope of MMP-2-mediated degradation 
of type VI collagen; CRPM = neo-epitope of MMP-1 and 8-mediated degradation of C-reactive protein; CT = computed tomography; ECG = electrocardiogram; eCRF = electronic 
case report form; EOT = End of Treatment; ET = Early Termination; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; hCG = human chorionic 
gonadotropin; ICF = informed consent form; IFN = interferon; IL = interleukin; MMP = matrix metalloproteinase; NIAID = National Institute of Allergy and Infectious Diseases; 
O = outpatient visit; PFT = pulmonary function test; PK = pharmacokinetic(s); PRO-C3 = released N-terminal pro-peptide of type III collagen; PRO-C4 = internal epitope in the 7S 
domain of type IV collagen; PRO-C6 = C-terminal of released C5 domain of type VI collagen α3 chain (endotrophin); reC1M = neo-epitope of MMP-2, 9-, and 13-mediated 
degradation of type I collagen; SpO2 = peripheral capillary oxygen saturation; TGF = transforming growth factor; TNF = tumor necrosis factor; WCBP = woman/women of 
childbearing potential; X-FIB (D-dimer) = neo-epitope of plasmin-mediated degradation of cross-linked fibrin.

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 70 of 74 
Version 3.0, 12 May 2021 
APPENDIX B: CLINICAL LABORATORY ANALYTES 
Screening and eligibility laboratory assessments may be performed at the local laboratory. All 
other laboratory assessments during the study will be assessed by a central laboratory.  
Standard Safety Chemistry Panel 
Alanine aminotransferase 
Albumin 
Alkaline phosphatase 
Amylase 
Aspartate aminotransferase 
Bicarbonate 
Blood urea nitrogen 
Calcium 
Chloride 
Creatine kinase 
Creatinine 
Estimated glomerular filtration rate 
Gamma-glutamyl transferase 
Glucose 
Inorganic phosphorus 
Lactate dehydrogenase 
Lipase 
Potassium 
Sodium 
Total bilirubin 
Total protein 
Uric acid 
 
Endocrinology 
Human chorionic gonadotropin (hCG) [1] 
 
1. hCG will be performed in women of childbearing potential only. 
 
Hematology 
Hematocrit 
Hemoglobin 
Platelets 
Red blood cell count 
White blood cell count and differential [1] 
 
1. Manual microscopic review will only be performed only if white blood cell count and/or differential values are out of reference 
range. 
 
Severe Acute Respiratory Syndrome Coronavirus-2 Testing 
Reverse transcriptase polymerase chain reaction (PCR) for severe acute respiratory syndrome 
(SARS) coronavirus (CoV)-2 or equivalent test [1]  
1. SARS-CoV-2 reverse transcriptase PCR may be performed at the Screening Visit, if not done previously. The patient must 
have a documented, laboratory-confirmed SARS-CoV-2 infection as determined by reverse transcriptase PCR (or an 
equivalent test) immediately prior to or during the current hospitalization. 
 
Viral Respiratory Panel [1] 
Influenza A [2] 
Influenza B  
Respiratory syncytial virus  
 
1. Additional viruses may be tested for at the Investigator’s discretion and based on local laboratory panels. Actual viruses tested 
for may vary depending on local standards of care. 
2. Influenza A may include H1 and H3 subtypes. 
 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 71 of 74 
Version 3.0, 12 May 2021 
Urinalysis 
Bilirubin 
Blood 
Creatinine  
Glucose  
Ketones  
Leukocyte esterase  
Microscopy [1]  
Nitrite  
pH  
Protein  
Specific gravity 
Urine albumin to creatinine ratio 
Urobilinogen 
 
1. Microscopy will only be performed as needed based on positive dipstick test results. 
 
Inflammatory and Fibrotic Biomarkers [1] 
C-reactive protein  
C4M 
C6M 
Connective tissue growth factor 
CRPM 
Cytokines [2] 
Ferritin  
MMP-7 
MMP-9 
MMP-12 
PRO-C3 
PRO-C4 
PRO-C6 
reC1M  
Transforming growth factor-β  
X-FIB (D-dimer) 
1. Additional biomarkers not listed here may be evaluated at a future date.  
2. Cytokines evaluated will include interferon-γ, tumor necrosis factor-α, IL-6, IL-1β, and C-C motif chemokine ligand 2 
(monocyte chemoattractant protein-1). 
C4M = neo-epitope of MMP-2, 9, and 12-mediated degradation of type IV collagen; C6M = neo-epitope of MMP-2-mediated 
degradation of type VI collagen; CRPM = neo-epitope of MMP-1 and 8-mediated degradation of C-reactive protein; 
IL = interleukin; MMP = matrix metalloproteinase; PRO-C3 = released N-terminal pro-peptide of type III collagen; 
PRO-C4 = internal epitope in the 7S domain of type IV collagen; PRO-C6 = C-terminal of released C5 domain of type VI collagen 
α3 chain (endotrophin); reC1M = neo-epitope of MMP-2, 9, and 13-mediated degradation of type I collagen; X-FIB 
(D-dimer) = neo-epitope of plasmin-mediated degradation of cross-linked fibrin. 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 72 of 74 
Version 3.0, 12 May 2021 
APPENDIX C: NATIONAL INSTITUTE OF ALLERGY AND 
INFECTIOUS DISEASES 8-POINT ORDINAL SCALE FOR COVID-19 
AND HOSPITALIZATION OUTCOMES 
Table 4. NIAID 8-Point Ordinal Scale for COVID-19 and Hospitalization Outcomes 
Numerical Score 
Definition  
1 
Death 
2 
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation 
3 
Hospitalized, on non-invasive ventilation or high-flow oxygen devices 
4 
Hospitalized, requiring supplemental oxygen 
5 
Hospitalized, not requiring supplemental oxygen – requiring ongoing medical care 
(COVID-19−related or otherwise) 
6 
Hospitalized, not requiring supplemental oxygen – no longer requires ongoing medical care 
7 
Not hospitalized, limitation on activities and/or requiring home oxygen 
8 
Not hospitalized, no limitation on activities 
COVID-19 = coronavirus disease 2019; NIAID = National Institute of Allergy and Infectious Diseases. 
Source: 
Adaptive 
COVID-19 
treatment 
trial 
(ACTT). 
NIH 
clinicaltrials.gov 
website. 
https://clinicaltrials.gov/ct2/show/NCT04280705. Accessed 09 November 2020 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 73 of 74 
Version 3.0, 12 May 2021 
APPENDIX D: SUGGESTED CRITERIA FOR MECHANICAL 
VENTILATION WEANING AND EXTUBATION 
Table 5. Suggested Criteria for Mechanical Ventilation Weaning and Extubation 
Suggested criteria for weaning  
FiO2 ≤40% and PEEP ≤8 cm of H2O or FiO2 <50% and PEEP ≤5 cm of H2O 
Acceptable spontaneous breathing efforts [1] 
Not receiving any neuromuscular blocking agents or blockade 
Suggested criteria for extubation [2] 
SpO2 ≥90% and/or PaO2 ≥60 mmHg 
Spontaneous tidal volume ≥4 mL/kg predicted body weight 
Respiratory rate ≤35 breaths per minute 
pH ≥7.3 
No respiratory distress [3] 
1. 
Acceptable spontaneous breathing efforts may be detected by decreasing the ventilation rate by 50% for 5 minutes.  
2. 
If the patient meets criteria for conducting a spontaneous breathing trial and has been in the study for at least 12 hours, a 
trial of up to 2 hours (120 minutes) of spontaneous breathing with FiO2 <50% and PEEP ≤5 cm H2O should be conducted. 
The patient should be placed on a T-piece, tracheostomy collar, or CPAP (≤5 cm H2O with pressure support ≤8 cm H2O). 
If the patient does not tolerate weaning, pre-weaning ventilator settings should be resumed. If tolerated for at least 
30 minutes, extubation may be considered.  
3. 
Respiratory distress is defined by at least 2 of the following: 
o 
Heart rate >120% of baseline; 
o 
Marked accessory muscle use; 
o 
Abdominal paradox; 
o 
Diaphoresis; or 
o 
Marked dyspnea. 
CPAP = continuous positive airway pressure; FiO2 = fractional inspired oxygen; PaO2 = arterial oxygen partial pressure; 
PEEP = positive end-expiratory pressure; SpO2 = peripheral capillary oxygen saturation. 
Sources:  
• 
National Institutes of Health. NIH NHLBI ARDS clinical network mechanical ventilation protocol summary. 
http://www.ardsnet.org/files/ventilator_protocol_2008-07.pdf. Accessed 29 June 2020 
• 
Schmidt GA, Girard TD, Kress JP, et al. Official executive summary of an American Thoracic Society/American College 
of Chest Physicians clinical practice guideline: liberation from mechanical ventilation in critically ill adults. Am J Respir 
Crit Care Med. 2017;195(1):115-119 

Foresee Pharmaceuticals, Co. Ltd. 
Clinical Study Protocol FP02C-20-001 
Confidential & Proprietary 
Page 74 of 74 
Version 3.0, 12 May 2021 
APPENDIX E: STRONG CLINICAL INHIBITORS AND INDUCERS FOR 
CYTOCHROME P450-MEDIATED METABOLISMS 
Table 6. Strong Inhibitors and Inducers of Cytochrome P450 
 
Strong Inhibitors 
Strong Inducers 
CYP1A2 
Ciprofloxacin, enoxacin, fluvoxamine [1] 
NA 
CYP2B6 
NA 
Carbamazepine [2] 
CYP2C8 
Gemfibrozil [3] 
NA 
CYP2C19 
 
Fluconazole [4], fluoxetine [5], 
fluvoxamine [1], ticlopidine 
Rifampin [6] 
CYP2D6 
Bupropion, fluoxetine [5], paroxetine, 
quinidine [7], terbinafine 
NA 
CYP3A 
Boceprevir, cobicistat [7], danoprevir and 
ritonavir [8], elvitegravir and ritonavir [8], 
grapefruit juice [9], indinavir and ritonavir [8], 
itraconazole [7], ketoconazole, lopinavir and 
ritonavir [7,8], paritaprevir and ritonavir (and 
ombitasvir and/or dasabuvir) [8], posaconazole, 
ritonavir [7,8], saquinavir and ritonavir [7,8], 
telaprevir [7], tipranavir and ritonavir [7,8], 
telithromycin, troleandomycin, voriconazole 
Apalutamide, carbamazepine [2] 
enzalutamide [10], mitotane, phenytoin [11], 
rifampin [6], St. John’s wort [12] 
Clarithromycin [7], idelalisib, nefazodone, 
nelfinavir [7] 
Note: Strong inhibitors are drugs that increase the AUC of sensitive index substrates of a given metabolic pathway ≥5-fold. 
Strong inhibitors of CYP3A causing ≥10-fold increase in AUC of sensitive index substrate(s) are shown in the second row to 
the right of “CYP3A.” 
Note: Strong inducers are drugs that decrease the AUC of sensitive index substrates of a given metabolic pathway by ≥80%. 
This table is prepared to provide examples of clinical inhibitors and inducers and is not intended to be an exhaustive list. 
1. 
Strong inhibitor of CYP1A2 and CYP2C19. Moderate inhibitor of CYP3A and weak inhibitor of CYP2D6. 
2. 
Strong inducer of CYP2B6 and CYP3A and weak inducer of CYP2C9. 
3. 
Strong inhibitor of CYP2C8 and inhibitor of OATP1B1 and OAT3. 
4. 
Strong inhibitor of CYP2C19 and moderate inhibitor of CYP2C9 and CYP3A. 
5. 
Strong inhibitors of CYP2C19 and CYP2D6. 
6. 
Strong inducer of CYP3A and moderate inducer of CYP1A2 and CYP2C19. 
7. 
Inhibitor of P-gp (defined as those increasing AUC of digoxin to ≥1.25-fold). 
8. 
Ritonavir is usually given in combination with other anti-HIV or anti-HCV drugs in clinical practice. Caution should be 
used when extrapolating the observed effect of ritonavir alone to the effect of combination regimens on CYP3A 
activities. 
9. 
The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation-dependent. 
Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation was used (eg, high 
dose, double strength) or as a “moderate CYP3A inhibitor” when another preparation was used (eg, low dose, single 
strength). 
10. Strong inducer of CYP3A and moderate inducer of CYP2C9, and CYP2C19. 
11. Strong inducer of CYP2C19, CYP3A, and moderate inducer of CYP1A2, CYP2B6, CYP2C8, and CYP2C9. 
12. The effect of St. John’s wort varies widely and is preparation-dependent. 
AUC = area under the concentration-time curve; CYP = cytochrome P450; HCV = hepatitis C virus; HIV = human 
immunodeficiency virus; NA = not applicable; OAT3 = organic anion transporter 3; OATP1B1 = organic anion transporting 
polypeptide 1B1; P-gp = P-glycoprotein.  
Source: United States Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors, 
and inducers. US Food and Drug Administration website. https://www.fda.gov/drugs/drug-interactions-labeling/drug-
development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table3-1. Accessed 23 March 2021.